

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
 Assistant Commissioner for Patents
 Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.
 Suite 1200, The Candler Building
 127 Peachtree Street, N.E.
 Atlanta, Georgia 30303-1811

April 15, 1997


Dear Sir:

Transmitted herewith for filing are the specification and claims of the patent application of:

Inventor(s): DAVID M. NEVILLE and STUART KNECHTLE

Title of Invention: METHODS OF INDUCING IMMUNE TOLERANCE USING
 IMMUNOTOXINS

Also enclosed are:

X	24 SHEETS OF	[X] FORMAL DRAWINGS	[] INFORMAL DRAWINGS
	OATH OR DECLARATION OF APPLICANT(S)		
	A POWER OF ATTORNEY		
	A PRELIMINARY AMENDMENT		
	A VERIFIED STATEMENT TO ESTABLISH SMALL ENTITY STATUS UNDER 37 C.F.R. §1.9 AND §1.27		
	A CHECK IN THE AMOUNT OF TO COVER THE FILING FEE.		
	THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY ADDITIONAL FEES WHICH MAY BE REQUIRED IN CONNECTION WITH THE FOLLOWING OR CREDIT ANY OVERPAYMENT TO ACCOUNT NO.		
	A CERTIFIED COPY OF PREVIOUSLY FILED FOREIGN APPLICATION NO. FILED IN ON .		
X	I hereby certify that this correspondence is being placed in the United States Mail as Express Mail No. EM424295393US on <u>15</u> day of <u>April</u> , 1997.  Harriet Rabun		
	DATE <u>4/15/97</u>		
X	A computer readable form of the sequence listing in compliance with 37 C.F.R. § 1.821(e) was filed with the provisional application, Ser. No. 60/015,459, on April 15, 1996. The content of the computer readable form of the sequence listing and the sequence listing in the specification of the application as filed are the same.		
	OTHER (IDENTIFY)		

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

TOTAL CLAIMS = $25 - 20 = 5 \times \$22.00 =$	110.00
INDEPENDENT CLAIMS = $1 - 3 = 0 \times \$80.00 =$	0
BASIC FEE =	\$770.00
TOTAL OF ABOVE CALCULATIONS =	880.00
REDUCTION BY 1/2 FOR SMALL ENTITY =	
TOTAL FILING FEE =	\$880.00

Respectfully submitted,



Gwendolyn D. Spratt
Registration No. 36,016

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
(404) 688-0770

08/26/99

Jc649 U.S. PTO

EXPRESS MAIL NO.: EL348125507US
ATTORNEY DOCKET NO. 14028.0292
SERIAL NO. 08/843,409
PAGE 1 OF 3 (08/26/99)

CONTINUING APPLICATION TRANSMITTAL FORM
(37 C.F.R. § 1.53(b))

Jc649 U.S. PTO

08/26/99

ANTICIPATED CLASSIFICATION OF THIS APPLICATION:

CLASS: 424

SUBCLASS: 178.1

PRIOR APPLICATION: 08/843,409

EXAMINER: S. Unger

ART UNIT: 1642

To the Assistant Commissioner for Patents:

This is a request for filing a divisional application under 37 C.F.R. 1.53(b), of pending prior application serial No. 08/843,409 filed on April 15, 1997, of David M. Neville, Judith M. Thomas and Stuart Knechtle for "METHODS OF INDUCING IMMUNE TOLERANCE USING IMMUNOTOXINS."

If any extension of time is necessary for the filing of this application, including any extension of time necessary in the prior application for maintaining copendency between the prior application and this application, and such extension has not otherwise been requested, Applicant hereby petitions for such an extension in the prior application.

1. Enclosed is a specification as prescribed by 35 U.S.C. § 112 containing a description pursuant to § 1.71 and at least one claim pursuant to § 1.75, and any drawing required by § 1.81(a)

2. The inventor(s) of the invention being claimed in this application is(are): David M. Neville, Stuart Knechtle and Judith M. Thomas

3A. ☒ This application is a continuation or divisional application (not a continuation-in-part) that:

(i) names as inventors the same or fewer than all of the inventors named in the prior application; and

(ii) contains no matter that would have been new matter in the prior application; and

(iii) a copy of the executed oath or declaration filed in the prior application, showing the signature or an indication thereon that it was signed:

☒ is enclosed.

☐ will follow.

☐ This application is being filed by less than all the inventors named in the prior application. In accordance with 37 C.F.R. § 1.53(d)(4), the Commissioner is requested to delete the name(s) of the following persons who are not inventors of the invention being claimed in this application:

--OR--

3B. ☐ This application is a continuation-in-part application, or a continuation or divisional application naming an inventor not named in the prior application. A newly executed oath or declaration.

☐ is enclosed.

☐ will follow.

4. ☐ Amend the Title of the Invention as follows:

5. ☒ Amend the specification by inserting before the first line the sentence:

This application is a divisional of, and claims the benefit of, application serial No. 08/843,409, filed April 15, 1997, which status is pending, which application is hereby incorporated herein by reference.

6. ☐ Priority of foreign application number, filed on in is claimed under 35 U.S.C. 119.

☐ The certified copy has been filed in prior application Serial No., filed on.

7. ☒ Cancel in this application original claims 11-21 and 23-25 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

8. ☒ A preliminary amendment is enclosed.

9. ☐ New formal drawings are enclosed.

10. ☐ Also enclosed is/are:

11. ☒ The prior application is assigned of record to: The Government of the United States of America, as represented by The Secretary, Department of Health and Human Services, c/o National Institutes of Health, Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852

12. ☐ A verified statement to establish small entity status under 37 C.F.R. 1.9 and 1.27:

☐ is enclosed

☐ was filed in prior application Serial Number and such status is still proper and desired (37 C.F.R. 1.28(a))

13. The filing fee is calculated as follows:

TOTAL CLAIMS	11 - 20 = 0	0	x \$18.00	\$0
INDEPENDENT CLAIMS	1 - 3 = 0	0	x \$78.00	\$0
MULTIPLE DEPENDENT CLAIM(S) (IF APPLICABLE) =			+ \$260.00	\$
BASIC FEE =				\$760.00
TOTAL OF ABOVE CALCULATIONS =				\$760.00
REDUCTION BY 1/2 FOR FILING BY SMALL ENTITY (NOTE 37 C.F.R. 1.9, 1.27, 1.28) IF APPLICABLE, AFFIDAVIT MUST BE FILED ALSO.				\$0
TOTAL NATIONAL FEE =				\$760

14. ☒ A check in the amount of \$760.00 is enclosed.

15. ☒ The Commissioner is hereby authorized to charge any fees which may be required under 37 C.F.R. 1.16 and 1.17, or credit any overpayment to Deposit Account No. 14-0629.

16. ☒ The Power of Attorney in the prior application is to: William H. Needle (Reg. No. 26,209); Sumner C. Rosenberg (Reg. No. 28,753); David G. Perryman (Reg. No. 33,438); Mitchell A. Katz (Reg. No. 33,919); Gregory J. Kirsch (Reg. No. 35,572); Gwendolyn D. Spratt (Reg. No. 36,016); Nagendra Setty (Reg. No. 38,300); Allan A. Altera (Reg. No. 40,274); Bryan W. Bockhop (Reg. No. 39,613); John L. Capone (Reg. No. 41,656); Kean J. DeCarlo (Reg. No. 39,954); LaVonda R. DeWitt (Reg. No. 40,396); D. Andrew Floam (Reg. No. 34,597); Bradley K. Groff (Reg. No. 39,695); Matthew D. Josephic (Reg. No. 43,699); David S. Kerven (Reg. No. 43,712); Janice A. Kimpel (Reg. No. 42,734); Tina W. McKeon (Reg. No. 43,791); Mary L. Miller (Reg. No. 39,303); Mark A. Murphy (Reg. No. 42,915); Lisa A. Samuels (Reg. No. 43,080); Clark G. Sullivan (Reg. No. 36,942); Elket V. Swope (Reg. No. 40,195); Lawrence A. Villanueva (Reg. No. 43,968); Mark A. Westhafer (Reg. No. 42,220);

- a. ☐ The Power of Attorney appears in the original papers in the prior application.
- b. ☒ Since the Power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. ☐ Address all future correspondence to: (May only be completed by applicant, or attorney or agent of record.)

Gwendolyn D. Spratt, Esq.
NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candlier Building
127 Peachtree Street, N.E.
Atlanta, GA 30303-1811

17. I hereby verify that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like are made punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Gwendolyn D. Spratt
REG. NO. 36,016



SIGNATURE

DATE

8-26-99

- ☐ Inventor(s)
- ☐ Assignee of complete interest
- ☒ Attorney or agent of record
- ☐ Filed under 37 C.F.R. 1.34(a)
(Registration No. is acting under 37 C.F.R. 1.34(a):

EXPRESS MAIL NO. EL348125507US

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Invoice No. EL348125507US in an envelope addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below


Kevin Lightburn

26 Aug '99
DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
)
Neville et al.)
) Group Art Unit: Unassigned
Serial No.: Unassigned)
Divisional Application under)
37 C.F.R. § 1.53(b) of)
Serial No. 08/843,409, filed April 15, 1997) Examiner: Unassigned
)
Filed: August 26, 1999)
)
For: "METHODS OF INDUCING IMMUNE)
TOLERANCE USING IMMUNOTOXINS")

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

Sir:

This Preliminary Amendment is submitted with the filing of the above-identified divisional application of U.S. Patent Application Serial No. 08/843,409, filed April 15, 1997. The parent application is being examined by Examiner S. Ungar of Art Unit 1642.

After assigning this divisional application a filing date and serial number and prior to examination, please amend the application as follows.

IN THE SPECIFICATION

On page 1, line 5, after "1996" insert --now abandoned --.

On page 1, line 7, after "application." insert the following sentence:

--This application also claims priority to U.S. Serial No. 08/739,703, filed
October 29, 1996.--

IN THE CLAIMS

Please cancel claim 11-21 and 23-25 without prejudice.

Please amend claim 1 as follows:

1. A method of inhibiting a rejection response in a primate recipient, by inducing immune tolerance [in a recipient,] to foreign mammalian donor cells, tissue or organ, comprising the steps of:
 - a) exposing the recipient to an anti-CD3-DT immunotoxin, wherein the immunotoxin comprises sFv-DT390, so as to [safely] reduce the recipients's T-cell lymphocyte population by at least 80%; and

- b) transplanting the donor cells, tissue or organ, into the recipient, such that a rejection response by the recipient to the donor cells, tissue or organ, is inhibited.

Please amend claim 22 as follows:

22. The method of claim 1, wherein the immunosuppressant is administered beginning from about 0 to 6 hours before the transplanting step [and continuing for up to several weeks after the transplant step].--

REMARKS

Original claims 11-21 and 23-25 are canceled herein without prejudice, and claims 1 and 22 are amended. The specification is amended herein to claim priority to a previously filed application. The amended claims incorporate some amendments made in the parent application and additionally provide that the anti-CD3-DT immunotoxin used in the claimed method comprises sFv-DT390. Support for the immunotoxin comprising sFv-DT390 can be found in the specification in Example 9. No new matter is believed to be added by these amendments.


The Examiner is invited and encouraged to directly contact the undersigned if such contact may enhance the efficient prosecution of this application to issue. No fees are believed to

ATTORNEY DOCKET NO. 14028.0292
SERIAL NO. Unassigned

be due. However, the Commissioner is hereby authorized to charge any fees due or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,


NEEDLE & ROSENBERG, P.C.




Gwendolyn D. Spratt
Registration No. 36,016

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
404/688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail No. EL348125507US in an envelope addressed to: BOX PATENT APPLICATION Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.



Kevin Lightburn



Date

EXPRESS MAIL NO. EM424295393US
ATTORNEY DOCKET NO. 14014.0225
PATENT

5

10

15

TO ALL WHOM IT MAY CONCERN:

20

Be it known that we, David M. Neville and Stuart
Knechtle, citizens of the United States of America,
residing, respectively, at 9624 Parkwood Drive, Bethesda,
Maryland 20814, and 2268 Caine Road, Oregon, Wisconsin
25 53575, U.S.A., have invented new and useful improvements
in

METHODS OF INDUCING IMMUNE TOLERANCE USING IMMUNOTOXINS

30 for which the following is a specification.

METHODS OF INDUCING IMMUNE TOLERANCE USING IMMUNOTOXINS

This application for letters patent claims priority under 35 U.S.C. § 119(e) of provisional patent application serial number 60/015,459, filed on April 15, 1996, having the same title of invention and the same inventors as the present application.

BACKGROUND OF THE INVENTION

10

Field of The Invention

This invention generally relates to an immunotoxin and to techniques for inducing immunological tolerance in primates. It appears to be especially well suited to provide a method for inhibiting rejection of transplanted organs. The invention further relates to a method of treating T cell leukemias or lymphomas, graft-versus-host diseases, and autoimmune diseases by administering an immunotoxin.

20

Background Art

The number of organ transplants performed in the United States is approximately 19,000 annually and consists predominantly of kidney transplants (11,000), liver transplants (3,600), heart transplants (2,300), and smaller numbers of pancreas, lung, heart-lung, and intestinal transplants. Since 1989 when the United Network for Organ Sharing began keeping national statistics, approximately 190,000 organ transplants have been performed in the United States. A large but difficult to ascertain number of transplants were performed in the United States prior to 1989 and a

similarly large number of transplants are performed in Europe and Australia and a smaller number in Asia.

Transplant tolerance remains an elusive goal for
5 patients and physicians whose ideal would be to see a
successful, allogeneic organ transplant performed without
the need for indefinite, non-specific maintenance
immunosuppressive drugs and their attendant side effects.
Over the past 10 years the majority of these patients have
10 been treated with cyclosporin, azathioprine, and
prednisone with a variety of other immunosuppressive
agents being used as well for either induction or
maintenance immunosuppression. The average annual cost of
maintenance immunosuppressive therapy in the United States
15 is approximately \$10,000. While the efficacy of these
agents in preventing rejection is good, the side effects
of immunosuppressive therapy are considerable because the
unresponsiveness which they induce is nonspecific. For
example, recipients can become very susceptible to
20 infection. A major goal in transplant immunobiology is
the development of specific immunologic tolerance to organ
transplants with the potential of freeing patients from
the side effects of continuous pharmacologic
immunosuppression and its attendant complications and
25 costs.

Anti-T cell therapy (anti-lymphocyte globulin) has
been used in rodents in conjunction with thymic injection
of donor cells (Posselt et al. *Science* 1990; 249: 1293-
30 1295 and Remuzzi et al. *Lancet* 1991; 337: 750-752).
Thymic tolerance has proved successful in rodent models
and involves the exposure of the recipient thymus gland to
donor alloantigen prior to an organ allograft from the

same donor. However, thymic tolerance has never been demonstrated in large animals, and its relevance to tolerance in humans is unknown.

5 One approach to try to achieve such immunosuppression has been to expose the recipient to cells from the donor prior to the transplant, with the hope of inducing tolerance to a later transplant. This approach has involved placement of donor cells (e.g. bone marrow)
10 presenting MHC Class I antigens in the recipient's thymus shortly after application of anti-lymphocyte serum (ALS) or radiation. However, this approach has proved difficult to adapt to live primates (e.g. monkeys; humans). ALS and/or radiation render the host susceptible to disease or
15 side-effects and/or are insufficiently effective.

If a reliable, safe approach to specific immunologic tolerance could be developed, this would be of tremendous value and appeal to patients and transplant physicians
20 throughout the world with immediate application to new organ transplants and with potential application to transplant recipients with stable function. Thus, a highly specific immunosuppression is desired.
Furthermore, there is a need for a means for imparting
25 tolerance in primates, without the adverse attributes of using ALS or radiation. Moreover, the goal is to achieve more than simply delaying the rejection response. Rather, an important goal is to inhibit the rejection response to the point that rejection is not a factor in reducing
30 average life span.

The present invention meets this need by providing a method of inducing immune tolerance.

SUMMARY OF THE INVENTION

It is an object of this invention to provide an immunotoxin for treating immune system disorders.

5

It is a further object of the invention to provide a method of treating an immune system disorder not involving T cell proliferation, comprising administering to the animal an immunotoxin comprising a mutant diphtheria toxin moiety linked to an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the disorder is treated. Thus, the present method can treat graft-versus-host disease.

15 It is a further object of the invention to provide a method of inducing immune tolerance. Thus, the invention provides a method of inhibiting a rejection response by inducing immune tolerance in a recipient to a foreign mammalian donor tissue or cells, comprising the steps of:

20 a) exposing the recipient to an immunotoxin so as to reduce the recipients's peripheral blood T-cell lymphocyte population by at least 80%, wherein the immunotoxin is anti-CD3 antibody linked to a diphtheria protein toxin, wherein the protein has a binding site mutation; and b)

25 transplanting the donor cells into the recipient, whereby a rejection response by the recipient to the donor organ cell is inhibited, and the host is tolerized to the donor cell.

30 The objects of the invention therefore include providing methods of the above kind for inducing tolerance to transplanted organs or cells from those organs. This and still other objects and advantages of the present

invention will be apparent from the description which follows.

BRIEF DESCRIPTION OF THE DRAWINGS

5

Figure 1 shows nude mice bg/nu/xid maintained in a semi-sterile environment are preconditioned with 400 cGy whole body ^{137}CS γ radiation on day -7. On day 0, 2.5×10^7 Jurkat cells (human T cell leukemia CD3+, CD4+, CD5+) are
10 injected subcutaneously with 1×10^7 HT-1080 feeder cells (human sarcoma) which have received 6000 cGy. Jurkat cells were passaged every other week in mice as subcutaneous tumors and dissociated by collagenase/dispase prior to inoculation. This cell population exhibits a 40%
15 inhibition of protein synthesis after 5 hours exposure to 10^{11}M anti-CD3-DT. Clones isolated from this population by infinite dilution exhibit varying sensitivity to anti-CD3-DT (4 less sensitive, 3 more sensitive) corresponding to a 1.5 log variation in dose response curves. Immunotoxin
20 treatment is given by intraperitoneal injection starting on day 7 when the tumor is visibly established. Evaluation takes place on day 37.

Figure 2 shows that the epitopes involved in human
25 serum's inhibition of toxicity lie in the last 150 amino acids of DT. A schematic diagram of the DT mutants CRM9, CRM197 and MSPA5 is presented (A). The A- and B-subfragments and their relative size and position are shown. The filled circle represents a point mutation as
30 described in the text. Goat (B) or human (C) serum (human serum was a pool from all samples with positive ELISA for anti-DT antibodies) was incubated with increasing molar concentrations of CRM197 (-O-), MSPA5 (-X-) or the

B-subfragment (-Δ-) of DT for 30 minutes at room temperature. To this reaction, UCHT1-CRM9 was added to a final concentration of 1×10^{-10} M. This mixture was then diluted 10-fold onto Jurkat cells in a protein synthesis inhibition assay as described in the Materials and Methods. Immunotoxin incubated with medium only inhibited protein synthesis to 4% of controls. The results are representative of two independent assays.

Figure 3 shows that sFv-DT390 maintains specificity for the CD3 complex but is 16-fold less toxic than UCHT1-CRM9 to Jurkat cells. A) Increasing concentrations of sFv-DT390 (-Δ-) or UCHT1-CRM9 (-O-) were tested in protein synthesis inhibition assays as described in the Materials and Methods. The results are an average of four separate experiments. B) Increasing concentrations of UCHT1 antibody were mixed with a 1×10^{-10} M UCHT1-CRM9 (-O-) or 3.3×10^{-10} M sFv-DT390 (-Δ-) and then added to cells for a protein synthesis inhibition assay.

Figure 4 shows the schematic flow sheet for generation of the single chain antibody scUCHT1 gene construct. PCR: polymerase chain reaction; L: linker; SP: signal peptide. P1 to P6, SP1, and SP2 are primers used in PCR, and listed in table 1.

Figure 5 shows the western blotting analysis of the single chain antibody scUCHT1. scUCHT1 was immunoprecipitated, and separated on 4-20% SDS/PAGE gradient gel. After transferring to Problott™ membrane, scUCHT1 was visualized by an anti-human IgM antibody labeled with phosphatase. scUCHT1 secreted was mainly a dimeric form. Lane 1-3 representing electrophoresis under

reducing conditions, and 4-6 non-reducing conditions. Lane 1 and 6 are human IgM; lane 1: IgM heavy chain. The light chain is not visible, because the anti-IgM antibody is directed at the heavy chain; lane 6: IgM pentamer is shown as indicated by the arrow. Lane 2 and 4 scUCHT1 from COS-7 cells; 3 and 5 scUCHT1 from SP2/0 cells.

Figure 6 shows that scUCHT1 had the same specificity and affinity as its parental antibody UCHT1. In the competition assay, ^{125}I -UCHT1 was used as tracer in binding Jurkat cells. scUCHT1 from COS-7 (\square) and SP2/0 cells (Δ), or unlabeled UCHT1 (\circ) with indicated concentrations were included as competitor. Results were expressed as a percentage of the ^{125}I -UCHT1 bound to cells in the absence of competitors.

Figure 7 shows that scUCHT1 did not induce human T cell proliferation response. scUCHT1 from COS-7 (Δ) and SP2/0 (\circ) cells and UCHT1 (\square) were added to human PBMCs at indicated concentrations and T cell proliferation was assayed by [3H]thymidine incorporation. UCHT1 induced a vigorous proliferation response. On the contrary, scUCHT1 had little effect at any doses.

Figure 8a shows that UCHT1 and scUCHT1 had little effect on TNF- α secretion, and. scUCHT1 from both COS-7 (Δ) and SP2/0 (\circ) cells and UCHT1 (\square) were added to cultures of human blood mononuclear cells. Culture supernatant was harvested and used for ELISA determination of TNF- α and IFN- γ as described in materials and methods.

Figure 8b shows that UCHT1 and scUCHT1 inhibited the basal production of IFN- γ . scUCHT1 from both COS-7 (Δ)

and SP2/0 (o) cells and UCHT1 (□) were added to cultures of human blood mononuclear cells. Culture supernatant was harvested and used for ELISA determination of TNF- α and IFN- γ as described in materials and methods.

5

Figure 9 is a western blot showing the secreted scUCHT1 immunotoxin.

Figure 10 shows a PCR amplification scheme.

10

Figure 11 shows one clone expressing the divalent immunotoxin fusion protein shown in Figure 13.

Figure 12 shows another clone expressing a divalent immunotoxin fusion protein shown in Fig. 14.

15

Figure 13 is a schematic of a divalent fusion immunotoxin.

Figure 14 is a schematic of a divalent fusion immunotoxin.

20

Figure 15 is a schematic of a divalent fusion immunotoxin.

25

Figure 16 shows the cloning scheme used to obtain scUCHT1 fusion protein with DTM1 and DT 483.

Figure 17 shows the cloning scheme used to obtain scUCHT1 fusion protein with DT 390.

30

Figure 18 shows the cloning scheme used to obtain scUCHT1 fusion protein with DT 370.

Figure 19a shows CD3+ cell depletion and recovery in peripheral blood following immunotoxin treatment. Days refer to days after the first dose of immunotoxin.

5 Figure 19b shows CD3+ cell depletion in lymph nodes following immunotoxin treatment.

Figure 20 shows the rise in serum IL-12 following FN18-CRM9 immunotoxin treatment in post kidney transplant
10 monkeys with and without treatment with DSG (deoxyspergualin) and solumedrol.

Figure 21 shows the rise in serum IFN-gamma following FN18-CRM9 immunotoxin treatment in post kidney transplant
15 monkeys with and without treatment with DSG and solumedrol. The treatment dramatically attenuates the rise of IFN-gamma.

Figure 22 shows that DSG and solumedrol treatment in
20 the peritransplant period following immunotoxin suppresses weight gain, a sign of vascular leak syndrome related to IFN-gamma elevation.

Figure 23 shows that DSG and solumedrol treatment in
25 the peritransplant period following immunotoxin suppresses hypoproteinemia, a sign of vascular leak syndrome related to IFN-gamma elevation.

DETAILED DESCRIPTION OF THE INVENTION

30

The invention provides immunotoxins and methods of using them to induce immune tolerance and to treat disease.

Immunotoxin.

The present invention relates to an immunotoxin. More specifically, an immunotoxin, comprising a mutant diphtheria toxin moiety linked to a single chain variable
5 region antibody which routes by the anti-CD3 pathway is provided. The immunotoxin can be divalent. The immunotoxin can be a fusion protein produced recombinantly. The antibody moiety of the immunotoxin can comprise the human CH2 and CH3 regions. These regions can
10 be from the antibody UCHT1 so that the antibody moiety is scUCHT1, which is a single chain CD3 antibody having human CH2 and CH3 regions and mouse variable regions as shown in the figures. These are the first instances of a sc anti-CD3 antibodies. Numerous DT mutant toxin moieties
15 are described herein, for example DT390. Thus, as just one specific example the immunotoxin, the invention provides scUCHT1-DT390. Derivatives of this immunotoxin are designed and constructed as described herein.

20 The toxin moiety retains its toxic function, and membrane translocation function to the cytosol in full amounts. The loss in binding function located in the C terminus of the protein diminishes systemic toxicity by reducing binding to non-target cells. Thus, the
25 immunotoxin can be safely administered. The routing function normally supplied by the toxin binding function is supplied by the targeting antibody anti-CD3. The essential routing pathway is (1) localization to coated pits for endocytosis, (2) escape from lysosomal routing,
30 and (3) return to the plasma membrane. Any antibody which can route in this manner will be effective with the toxin moiety, irrespective of the epitope to which the antibody is directed. Thus, a wide variety of cell types can in

principle be targeted. When antibodies dissociate from their receptors due to changes in receptor configuration induced in certain receptors as a consequence of endosomal acidification, they enter the lysosomal pathway. This can
5 be prevented or minimized by directing the antibody towards an ecto-domain epitope on the same receptor which is closer to the plasma membranes (Ruud, et al. (1989) *Scand. J. Immunol.* 29:299; Herz et al. (1990) *J. Biol. Chem.* 265:21355). Other DT binding site mutants can be
10 used to form derivatives by changing amino acids in the C-terminus which can reduce the binding function as long as the translocation function is maintained. Specific examples are described in the Examples.

15 In another embodiment, the present invention relates to an anti-CD3-CRM9 immunotoxin or derivatives thereof. The design of successful derivatives of anti-CD3-CRM9 depend upon understanding how the unique concentration of anti-CD3-CRM9 achieves its biological effect.

20 An example of a series of derivatives which is likely to be effective are antibody-CRM9 conjugates directed at unique V α and V β gene segment products of the T cell receptor. Some of these epitopes appear to be biased
25 towards specific autoimmune processes. Such conjugates should be useful in specific autoimmune diseases (Kappler et al. (1987) *Cell* 49:263; Urban et al. (1988) *Cell* 54:577).

30 Relatedly, the invention provides an anti-V β -CRM9 immunoconjugate such as anti-V β_{12} -CRM9. Also provided is an anti-V α -CRM9 immunoconjugate. Both of the conjugates can be placed in a pharmaceutically acceptable carrier for

administration to a subject. Both acid-cleavable and non-cleavable protein cross-linking reagents can be used in the construction of antibody-diphtheria toxin binding-site mutant conjugates like anti-CD3-CRM9 (Neville et al. (1989) *J. Biol. Chem.* 264:14653-14661); preferred are non-cleavable crosslinkers, such as bismaleimido-hexane and m-maleimidobenzoyl-N-hydroxysuccinimide ester. The synthesis of acid-cleavable protein cross-linking reagents based on orthoester, acetal, and ketal functionalities has been described (Srinivasachar and Neville (1989) *Biochemistry* 28:2501-2509). The unique feature of these functionalities is that their observed hydrolytic rate constants increase 10-fold for each drop in pH, a consequence of specific H_3O^+ catalysis leading to a carbonium ion intermediate (Cordes and Bull (1974) *Chem. Rev.* 74:581-603). Moreover, these functionalities are resistant to base catalysis permitting manipulation and storage at alkaline pH. The cross-linking reagents react with proteins via heterobifunctional groups (maleimide and N-hydroxysuccinimide ester) or homobifunctional groups (bis-maleimide). The maleimide cross-linking is accomplished by prior protein thiolation with iminothiolane. Cross-linked proteins exhibit first-order dissociation under acid conditions. The $t_{1/2}$ at pH 5.5 varies between 0.1 and 130 h for a series of six different cleavable cross-linkers (Srinivasachar and Neville (1989) *Biochemistry* 28:2501-2509).

The mutant diphtheria toxin moiety can be a truncated mutant, such as DT390, DT383, DT370 or other truncated mutants, as well as a full length toxin with point mutations, such as DTM1, as described in Examples 9-11. scUCHT1 fusion proteins with DTM1 and DT483 (see Fig.

16), DT390 (Fig. 17) and DT370 (Fig. 18) have been cloned and expressed in *E. coli*. The antibody moiety can be scUCHT1 or other anti-CD3 antibody having the characteristics set forth herein. Thus, one example of an immunotoxin for use in the present methods is UCHT1-DT390. The described immunotoxins can be used in all the methods of the invention.

Other examples of immunotoxins include anti-V β -CRM9 and anti-V α -CRM9. For example, the antibody-CRM9 conjugate used in any of the methods herein can be an anti-V β -CRM9 such as anti-V β_8 -CRM9. In addition, the antibody-CRM9 conjugate can be an anti-V α -CRM9. In one embodiment, the anti-V β -CRM9 is anti-V β_{12} -CRM9 and the disease is human immunodeficiency virus disease or the Acquired Immunodeficiency Syndrome (AIDS). Other V α and V β targets associated with particular autoimmune diseases exist. For example, pulmonary sarcoidosis showed increased usage of the V β_8 subset in blood and lung lymphocytes (Moller et al. (1988) *J. Clin. Invest.* 82:1183-1191). In multiple sclerosis, preferential use of the V $\beta_{5.2}$ subset in brain plaque lesions has been identified and rearrangements Of V $\alpha_{1,2,7,8, \text{ and } 10}$ were also prominent (Oksenberg et al. (1993) *Nature* 362:68-70).

25

The antibody-toxin constructs of the invention can be expected to be effective as immunotoxins, because the relevant parameters are known. The following discussion of parameters is relevant to the use of the immunotoxin in tolerance induction. The relevant binding constants, number of receptors and translocation rates for humans have been determined and used. Binding values for anti-CD3-CRM9 for targeted and non-targeted cells *in vitro* are

described above at page 2. Rates of translocation for the anti-CD3-CRM9 conjugate to targeted and non-targeted cells *in vitro* are described in references cited at page 2 (Greenfield et al. (1987) *Science* 238:536; Johnson et al. (1988) *J. Biol. Chem.* 263:1295; Johnson et al. (1989) *J. Neurosurg.* 70:240; and Neville et al. (1989) *J. Biol. Chem.* 264:14653). The rate limiting translocation rate to targeted cells *in vitro* is recited at page 5, wherein it is shown that the conjugate is translocated to about 40% of the target cells present as measured by inhibition of protein synthesis in about 40% of cells. Inhibition of protein synthesis is complete in cells into which the conjugate translocates.

Parameters determined in *in vivo* studies in nude mice include the following: Tumor burden is described in Example 1 as a constant mass equal to 0.1% of body weight; the receptor number and variation of receptor number are described in Example 3; "favorable therapeutic margin" is defined as an *in vivo* target cell 3 log kill at 0.5 MLD (minimum lethal dose) comparison of efficacy with an established treatment of 0.5 MLD immunotoxin equivalent (group 1) to a radiation dose of 500-600 cGy (groups 8 and 9).

25

The parameters determined *in vitro* allowed the prediction of success in the *in vivo* nude mouse study. The prediction of *in vivo* success was verified by the data in Examples 3-4. Using the target cell number from the mouse study as being equivalent to the local T cell burden in a monkey or man successful T cell ablation and immunosuppression in monkeys could be predicted. This

prediction has been verified by the monkey data in
Examples 5 and 7-8. Using the same parameters, a
scientist skilled in this field can make a prediction of
success in humans with confidence, because these
5 parameters have been previously shown to have predictive
success.

In another embodiment, the present invention relates
to a pharmaceutical composition comprising anti-CD3-DT
10 mutant in an amount effective to treat T cell leukemias or
lymphomas which carry the CD3 epitope, graft-versus-host
disease or autoimmune diseases, and a pharmaceutically
acceptable diluent, carrier, or excipient. One skilled in
the art will appreciate that the amounts to be
15 administered for any particular treatment protocol can
readily be determined. Suitable amounts might be expected
to fall within the range of 0.01 to 1.0 mg (toxin content)
per kg of body weight.

20 **Non-toxic mutant of diphtheria toxin.**

Most human sera contain anti-DT neutralizing
antibodies from childhood immunization. To compensate for
this the therapeutic dose of anti-CD3-CRM9 can be
appropriately raised without affecting the therapeutic
25 margin. Alternatively, the present application provides a
non-toxic DT mutant reactive with neutralizing antisera
(e.g., CRM197) that can be administered in conjunction
with the immunotoxin.

30 A non-toxic mutant of diphtheria toxin for use in the
present methods can be DTM2 or CRM197. DTM2 and CRM197
are non-toxic mutants of DT, having a point mutation in
the enzymatic chain. However, they have the full

antigenic properties of DT and CRM9, and CRM197 is used for immunization (Barbour et al. 1993. *Pediatr Infect. Dis. J.* 12:478-84). Other non-toxic DT mutants that can be used in the present method will share the
5 characteristic of totally lacking A chain enzymatic activity.

The purpose of administering the non-toxic toxin is to bind preexisting anti-CRM9 and anti-DT antibodies in a
10 subject and compete with their effect and/or induce their removal from the circulation. This substantially avoids any host immune response to the immunotoxin that might interfere with the activity of the immunotoxin.

15 The protein synthesis inhibition assay in the presence of human serum samples or pooled human sera described in the Examples becomes an important part of the evaluation of the optimal immunotoxin for the individual patient and is provide for this purpose. This assay makes routine the
20 systematic evaluation of additional combinations of DT point mutations and carboxy-terminal deletions for the purpose of minimizing blockade of immunotoxin *in vivo* by anti-human antitoxin.

25 The non-toxic mutant is preferably administered concurrently with or shortly before the immunotoxin. For example, the non-toxic DT mutant can be administered within an hour, and preferably about 5 minutes prior to the administration of immunotoxin. A range of doses of
30 the non-toxic mutant can be administered. For example, an approximately 10 to 100 fold excess of non-toxic mutant over the CRM9 content of the immunotoxin to be administered can be administered by I.V. route.

Another use of the non-toxic DT mutant in the present methods is to run the recipient patient's blood through a column containing the non-toxic DT mutant to remove some or all of the patient's serum antibodies against DT.

5

Method of Inducing Immune Tolerance.

One embodiment to the invention provides a method of inhibiting a rejection response by inducing immune tolerance in a recipient to a foreign mammalian donor organ cell by safely exposing the recipient to an immunotoxin so as to reduce the recipients's peripheral blood T-cell lymphocyte population by at least 80%, and preferably 95% or higher, wherein the immunotoxin is an anti-CD3 antibody linked to a diphtheria protein toxin, and wherein the protein has a binding site mutation. The term "safely" in this context means that recipient is not killed by the immunotoxin. The term "donor cell" refers to a donor organ or a cell or cells of the donor organ, as distinguished from donor lymphocytes or donor bone marrow. When the donor organ or cells of the donor is transplanted into the recipient, a rejection response by the recipient to the donor organ cell is inhibited and the recipient is tolerized to the donor organ cell. Alternatively, a non-toxic DT mutant such as DTM2 or CRM197 can first be administered followed by the immunotoxin. This method can use any of the immunotoxins (e.g., anti-CD3-CRM9, scUCHT1-DT390, etc.) or non-toxic DT mutants described herein with the dosages and modes of administration as described herein or otherwise determined by the practitioner.

30

As further described in the Examples, the above-described method for inducing tolerance can be augmented by additional treatment regimens. For example, the method

can further include administering to the thymus gland a thymic apoptosis signal before, at the same time, or after, the immunotoxin exposure step. The thymic apoptosis signal can be high dose corticosteroids (also referred to as "immunosuppressants" in this context). The thymic apoptosis signal can be lymphoid irradiation.

In a further example of the method of inducing tolerance, thymic injection of donor leukocytes or lymphocytes having MHC antigen of the same haplotype as the MHC of the donor cell can be administered to the recipient. Thymic injection of a saline solution or a crystalloid or colloid solution to disrupt thymic integrity and increase access of immunotoxin to the thymus can also be beneficial.

The present tolerance induction method can also include administering an immunosuppressant compound before, at the same time, or after, the immunotoxin exposure step. The immunosuppressant compound can be deoxyspergualin, cyclosporin or other cyclophylins, mycophenolate mofetil (Roche), FK506, IL-12 inhibitors or other known immunosuppressants. The method of inducing immune tolerance can further comprise administering donor bone marrow at the same time, or after, the exposure step.

Any one, two, or more of these adjunct therapies can be used together in the present tolerance induction method. Thus, the invention includes at least six methods of inducing tolerance using immunotoxin (IT): (1) tolerance induction by administering IT alone; (2) tolerance induction by administering IT plus other drugs that alter thymic function such as high dose

corticosteroids; (3) tolerance induction by administering IT plus immunosuppressant drugs such as cyclosporin (4) tolerance induction by administering IT plus other drugs that alter thymic function, plus immunosuppressant drugs; 5 (5) tolerance induction by administering IT and bone marrow; and (6) tolerance induction by administering IT plus bone marrow, plus other drugs that alter thymic function, plus immunosuppressant drugs. The adjunct therapy can be administered before, at the same time or 10 after the administration of immunotoxin. Different adjunct therapies can be administered to the recipient at different times or at the same time in relation to the transplant event or the administration of immunotoxin, as further described below.

15

Because the immunosuppressant can be administered before the immunotoxin and/or other treatments, the present method can be used with a patient that has undergone an organ transplant and is on an 20 immunosuppressant regimen. This presents a significant opportunity to reduce or eliminate traditional immunosuppressant therapy and its well documented negative side-effects. Also, as described below, treatment with immunosuppressants prior to transplantation could be 25 particularly useful in cadaveric transplants. In such a setting of pre-transplant treatment with immunosuppressant, the administration of immunotoxin can be advantageously delayed for up to seven or more days post-transplantation.

30

An example of a schedule of immunotoxin and immunosuppressant administration for patients receiving live organ transplants is as follows:

ATTORNEY DOCKET NO. 14014.0225

day -7 to day 0: begin immunosuppressant treatment;
day 0 : perform transplant;
day 7 : begin immunotoxin and non-toxic DT
toxin treatment;
5 day 9 : end immunotoxin treatment;
day 11 : end immunosuppressant treatment.

In another example, non-toxic DT mutant is
administered seven days before the transplant and
10 immunotoxin is administered seven days after the
transplant.

The immunotoxin injection can also be made within a
week or two prior to the donor cell treatment. If the
15 donor organ or cell from donor organ is from a live donor,
the immunotoxin is preferably administered from 15 hours
to 7 days before the transplanting step. If the donor
organ is kidney or kidney cells and is from a cadaver, the
immunotoxin is preferably administered from 6 to 15 hours
20 before the transplanting step. If the donor organ or cell
from the donor organ is from a cadaver and is selected
from the group consisting of heart, lung, liver, pancreas,
pancreatic islets and intestine, the immunotoxin is
preferably administered from 0 to 6 hours before the
25 transplanting step. For practical reasons immunotoxin
treatment and transplantation generally take place at
about the same time (e.g., within 15 hours), because
advanced planning for cadaveric transplants is difficult.
Various schedules of apoptotic and immunosuppressant
30 therapies can be used with the above methods. In any of
the above scenarios, donor bone marrow, if desired, can be
administered at approximately the time of the transplant
or after.

The preferred doses of the immunotoxin are those sufficient to deplete peripheral blood T-cell levels to 80%, preferably 90% (or especially preferably 95% or higher) of preinjection levels. This should require mg/kg
5 levels for humans similar to those for monkeys (e.g. 0.15 mg/kg to 0.2 mg/kg body weight), which toxicity studies indicate should be well tolerated by humans. Thus, the immunotoxin can be administered to safely reduce the recipients T cell population.

10

Method of Treating Graft-Versus-Host Disease.

In another embodiment, the invention relates to a method of treating an immune system disorder not involving T cell proliferation which is amenable to T cell
15 suppression. More specifically, a method of treating graft-versus-host disease in an animal is also provided. It comprises administering to the animal an immunotoxin comprising a diphtheria toxin binding mutant moiety and an antibody moiety which routes by the anti-CD3 pathway, or
20 derivatives thereof under conditions such that the graft-versus-host disease is treated, i.e., the symptoms of the graft-versus-host disease improve. Alternatively, as further described, a non-toxic DT mutant such as DTM2 or CRM197 (or mutants having combinations of the mutations in
25 CRM9 and CRM197) can first be administered followed by the immunotoxin. This method can use any of the immunotoxins or non-toxic DT mutants described herein with the dosages and modes of administration as described herein or otherwise determined by the practitioner.

30

GVHD is a morbid complication of bone marrow transplantation which is often performed as anti-leukemia/lymphoma therapy. GVHD is caused by circulating

donor T cells within the host which are acquired in bone marrow grafts unless specifically depleted prior to grafting (Gale and Butturini (1988) *Bone Marrow Transplant* 3:185; Devergie et al. (1990) *ibid* 5:379; Filipovich et al. (1987) *Transplantation* 44). Successful donor T cell depletion techniques have been associated with a higher frequency of graft rejection and leukemia relapses (Gale and Butturini (1988) *Bone Marrow Transplant* 3:185; Devergie et al. (1990) *ibid* 5:379; Filipovich et al. (1987) *Transplantation* 44). Therefore, the donor T cells appear to aid engraftment and to provide a graft-versus-leukemia effect as well as causing GVHD. Because the T cell burden following bone marrow transplantation is low for the first 14 days (<10% of normal) the log kill of donor T cells would be proportionally enhanced (Marsh and Neville (1987) *Ann. N.Y. Acad. Sci.* 507:165; Yan et al., submitted; Gale and Butturini (1988) *Bone Marrow Transplant* 3:185; Devergie et al. (1990) *ibid* 5:379; Filipovich et al. (1987) *Transplantation* 44). It is expected that donor T cells can be eliminated at set times during the early post transplantation period using the present method. In this way the useful attributes of grafted T cells might be maximized and the harmful effects minimized.

25

Method of Treating an Autoimmune Disease.

Another embodiment of the invention provides a method of treating an autoimmune disease in an animal comprising administering to the animal an immunotoxin comprising a diphtheria toxin binding mutant moiety and an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the

ATTORNEY DOCKET NO. 14014.0225

autoimmune disease is treated, e.g., the symptoms of the autoimmune disease improve. A further method of treating an autoimmune disease in an animal comprises administering to the animal a non-toxic mutant of diphtheria toxin
5 followed by an antibody CRM9 conjugate which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated. This method can use any of the immunotoxins or non-toxic DT mutants described herein with the dosages and modes of
10 administration as described herein or otherwise determined by the practitioner.

Method of Treating T Cell Leukemias or Lymphomas.

A further embodiment of the invention provides a
15 method of treating T cell leukemias or lymphomas which carry the CD3 epitope in an animal comprising administering to the animal an immunotoxin comprising a binding site mutant of diphtheria toxin moiety and an antibody moiety which routes by the anti-CD3 pathway, or
20 derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated. Alternatively, a further embodiment is a method of treating T cell leukemias or lymphomas in an animal comprising administering to the animal a non-toxic mutant of
25 diphtheria toxin followed by an antibody-CRM9 conjugate which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated. This method can use any of the immunotoxins or non-toxic DT mutants described herein with
30 the dosages and modes of administration as described herein or otherwise determined by the practitioner.

Method of Treating Acquired Immunodeficiency Syndrome.

A method is provided for treating acquired immunodeficiency syndrome in an animal, comprising administering to the animal an immunotoxin comprising a diphtheria toxin binding mutant moiety and an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the acquired immunodeficiency syndrome is treated. Alternatively, a method of treating acquired immunodeficiency syndrome in an animal, comprising administering to the animal a non-toxic mutant of diphtheria toxin followed by an antibody-CRM9 conjugate which routes by the anti-CD3 pathway or derivatives thereof under conditions such that the acquired immunodeficiency syndrome is treated is provided. This method can use any of the immunotoxins or non-toxic DT mutants described herein with the dosages and modes of administration as described herein or otherwise determined by the practitioner. However, anti-V β_{12} is a likely conjugate for use in this method.

20

Radiation induced T cell ablation with concomitant high dose zidovudine therapy followed by bone marrow transplantation has been reported to eradicate HIV-1 infection in one case (Holland et al. (1989) *Ann. Int. Med.* 111:973). Cyclophosphamide, a T cell suppressive reagent, has been shown to be beneficial in treating murine AIDS (Simard and Joliceur (1991) *Science* 251:305). Anti-CD3-CRM9 provides extensive T cell ablation without the requirement of bone marrow reconstitution.

30

In any of the methods recited, a H1 histamine blocking agent such as Benadryl or Tavegil can be administered I.V. prior to administering the non-toxic

mutant to minimize any possibility of an anaphylactic reaction. No evidence of anaphylactic reaction was noted in the primate experiments described in the Examples. However, the H1 histamine blocker can be administered as a precaution with no significant disadvantage.

The immunotoxin described here is more toxic on a weight basis than hemi-immunotoxins, but at tolerated doses exhibits an apparent log kill of targeted cells at target cell burdens encountered clinically. This constitutes a favorable therapeutic margin. Most human sera contain anti-DT neutralizing antibodies from childhood immunization (Johnson et al. (1989) *J. Neurosurg.* 70:240). To compensate for this the therapeutic dose of anti-CD3-CRM9 can be appropriately raised without affecting the therapeutic margin. The doses for immunotoxin and, where used, the non-toxic DT mutant are described in the Examples.

The present invention will be illustrated in further detail in the following non-limiting examples.

EXAMPLE 1

25

Establishment of Tumors

The experimental design of the studies that give rise to the present invention was dictated by the goal of having an animal model as closely relevant to human *in vivo* tumor therapy as possible. In order to minimize the host killer cell immune response, bg/nu/xid strain of nude mice were used (Kamel-Reid and Dick (1988) *Science* 242:1706). The human T cell leukemia cell line, Jurkat,

ATTORNEY DOCKET NO. 14014.0225

was chosen because of previous studies with this line and its relatively normal average complement of CD3 receptors (Preijers et al. (1988) *Scand. J. Immunol.* 27:553). The line was not cloned so that receptor variation among individual cells existed (Figure 1 legend). A scheme was developed whereby well established tumors of constant mass equal to 0.1% of body weight ($\approx 4 \times 10^7$ cells) could be achieved 7 days after inoculation of Jurkat cells (see Figure 1 and Dillman et al. (1988) *Cancer Res.* 15:5632). This required prior irradiation and inoculation with lethally irradiated helper feeder cells (see Figure 1 and Dillman et al. (1988) *Cancer Res.* 15:5632).

EXAMPLE 2

15

Guinea Pig Studies

Immunotoxin toxicity studies were performed in guinea pigs, an animal (like humans) with a high sensitivity to diphtheria toxin (mice are highly resistant to diphtheria toxin). Therapy of CRM9 conjugates was set at 1/2 the guinea pig minimum lethal dose. In this study, minimum lethal dose (MLD) is defined as the minimum tested dose which results in both non-survivors and survivors over a 4 week evaluation period. All animals survive when a MLD is reduced by 0.5. MLD was evaluated in guinea pigs (300-1000 g) by subcutaneous injection. The following MLDs were found and are listed as μg of toxin/kg body weight; DT, 0.15; CRM9, 30; anti-CD5-DT (cleavable), 0.65; anti-CD5-CRM9 (non-cleavable), 150. Finally, the therapeutic efficacy of the immunotoxin treatment in producing tumor regressions was compared to graded doses of whole body irradiation which resulted in similar tumor regressions.

EXAMPLE 3

Comparison of Immunotoxins

5 Several types of immunotoxins were compared in this study. They were synthesized as previously described by thiolating both the monoclonal antibody moiety and the toxin moiety and then crosslinking the bismaleimide crosslinkers (Neville et al. (1989) *J. Biol. Chem.* 264:14653). Purification was performed by size exclusion HPLC columns and fractions containing 1:1 toxin:antibody mol ratios were isolated for these studies. Conjugates made with an acid-labile crosslinker bismaleimidoethoxy propane were compared with a non-cleavable, bismaleimidohexane. Conjugates made with this cleavable crosslinker have been shown to hydrolyze within the acidifying endosome releasing free toxin moieties with half-times of hydrolysis measured at pH 5.5 of 36 min (Neville et al. (1989) *J. Biol. Chem.* 264:14653).

20 The results of this study are tabulated in Table I. Non-treatment groups such as group 10, groups treated with anti-CD5 immunotoxins (groups 5 and 6), and group 4 treated with a mixture of anti-CD3 and CRM9 did not show regression. The vascularized tumor nodules that weighed 20 mg on day 7 grew to between 1.5 to 7.8 g on day 37 and weighed between 7.9 and 11.6 on day 56. No late spontaneous regressions were noted. In contrast, group 1 consisting of treatment with anti-CD3-CRM9 non-cleavable conjugate (NC) given at 25 µg/kg on days 7, 8, and 9 (see Figure 1 time line) showed only 1 tumor out of 6 by day 37. Some of the remaining animals were subject to autopsy and they failed to reveal residual tumor or even scarring.

[illegible]

ATTORNEY DOCKET NO. 14014.0225

TABLE 1. IMMUNOTOXIN AND RADIATION TREATMENT ON SUBCUTANEOUS HUMAN T CELL TUMORS (JURKAT) IN NUDE MICE

Group	Treatment	Dose (intraperitoneal)	Animals Bearing Tumors At Day 37/Group Animals	% Tumor Regressions
1	Anti-CD3-CRM9 (NC)*	25 µg/kg. x 3d	1/6	83
2	Anti-CD3-CRM9 (NC)	19 µg/kg. x 2d	1/4	75
	Anti-CD5-CRM9 (C)	19 µg/kg. x 2d		
3	Anti-CD3-CRM9 (C)	25 µg/kg. x 3d	2/4	50
4	Anti-CD3+CRM9	25 µg/kg. x 3d	4/4	0
5	Anti-CD5-CRM9 (C)	25 µg/kg. x 3d	5/5	0
6	Anti-CD5-DT (NC)	25 µg/kg. x 1d	9/9	0
7	γ radiation ¹³⁷ Cs	400 cGy	2/2	0
8	γ radiation ¹³⁷ Cs	500 cGy	3/6	50
9	γ radiation ¹³⁷ Cs	600 cGy	0/2 ^b	100
10	None		6/6	0

*Anti-CD3 refers to the monoclonal antibody UCHT1 and was purchased from Oxoid USA, Inc. Anti-CD5 refers to the monoclonal antibody T101 and was a gift from Hybritech (San Diego). NC and C refer, respectively, to non-cleavable and cleavable conjugates.

^bThese animals were evaluated on days 10 and 13 at the time of death from radiation sickness.

The cleavable crosslinker confers no therapeutic advantage to anti-CD3-CRM9 immunotoxins and may be less effective (group 3). Cleavable crosslinkers confer some advantage with anti-CD5-CRM9 conjugate in vitro (5) but
5 had no effect in this in vivo system (group 5), and lacked significant potentiating effect when administered with anti-CD3-CRM9 (group 2). The cleavable crosslinker conferred a marked therapeutic advantage to anti-CD5 wild type toxin conjugates and tumor regressions were achieved.
10 However, in these cases the guinea pig toxic dose was exceeded. A single dose on day 7 of cleavable anti-CD5-DT at 6 $\mu\text{g}/\text{kg}$ produced 8/10 tumor regressions while a cleavable conjugate made with an irrelevant antibody (OX8) produced no regressions (4/4). However, this dose
15 exceeded the guinea pig MLD by 9 fold. A rescue strategy was tried in which the above conjugate dose was given intravenously followed by DT antitoxin 4 hours later (also intravenously). The 4 hr rescue could not raise the MLD above 0.65 $\mu\text{g}/\text{kg}$. The 1 hr rescue could not raise the MLD
20 above 0.65 $\mu\text{g}/\text{kg}$. The 1 hr rescue raised the MLD to 36 $\mu\text{g}/\text{kg}$, however, there were no tumor regressions in 10 mice receiving 21.5 $\mu\text{g}/\text{kg}$ of the cleavable anti-CD5-DT conjugate.

25 In groups 7-9 increasing single doses of whole body radiation (102 cGy/min) were given to animals bearing 3x3x5 mm tumors. At 400 cGy no complete regressions occurred. At 500 cGy 50% complete tumor regressions occurred. At 600 cGy 100% regression was achieved as
30 judged on day 10 and 13 when the animals died from radiation sickness. (Groups 7-9 did not receive prior radiation and tumor takes were less than 100%). It appears that the 75 $\mu\text{g}/\text{kg}$ anti-CD3-CRM9 (NC) immunotoxin

EXAMPLE 4

Estimation of Cell Kill

The actual cell kill achieved by the radiation and the immunotoxin can be estimated by assuming radiation single hit inactivation kinetics along with a D_{37} value for the radiation. A value for D_{37} of 70-80 cGy with $n = 1.2-3$ is not unreasonable for a rapidly dividing helper T cell. D_{37} is the dose of radiation which reduces the fraction of surviving cells to $1/e$ as extrapolated from the linear portion of the log survivors vs. dose curve and n is the intercept at 0 dose (Anderson and Warner (1976) in *Adv. Immunol.*, Academic Press Inc., 24:257). At a dose of 550 cGy the fraction of surviving cells is calculated to be about 10^3 . Since a majority of tumors completely regress at this dose, it is estimated that both therapies are producing an approximate 3 log kill. (The remaining cells, $4 \times 10^7 \times 10^3 = 4 \times 10^4$ cells apparently cannot maintain the tumor, i.e., the *in vivo* plating efficiency is low, a fairly typical situation in the nude mouse xenograft system.) The reliability of this 3 log kill estimate has been verified by determining the tissue culture plating efficiency by limiting dilution of 7 day established Jurkat tumors (following dispersal) and tumors exposed 18 hours earlier *in vivo* to 600 cGy. Plating efficiencies were 0.14 and 1.4×10^4 , respectively. (Plating efficiency is the reciprocal of the minimum average number of cells per well which will grow to form one colony.

It should be emphasized that with high affinity holo-immunotoxins the cell kill is inversely proportional to the target cell number. This presumably occurs because receptors are undersaturated at tolerated doses and free conjugate concentration falls with increasing target cell burden (Marsh and Neville (1987) *Ann. N.Y. Acad. Sci.* 507:165; Yan et al. (1991) *Bioconjugate Chem.* 2:207). To put this in perspective, the tumor burden in this study is almost equal to the number of T cells in a mouse ($\approx 10^8$). It can be expected that a tolerated dose of anti-CD3-CRM9 immunotoxin can achieve an *in vivo* 3 log depletion of a normal number of CD3 positive T cells.

EXAMPLE 5

15

Cell Depletion in Rhesus Monkeys Induced by FN18-CRM9

FN18-CRM9 conjugate.

20 Conjugation of anti-V β and anti-V α IgG monoclonal antibodies to CRM9 is performed by the same methods used to conjugate anti-CD3 to CRM9 using a non-cleavable linker such as bismaleimido-hexane and previously described in detail (Neville et al. (1988) *J. Biol. Chem.* 264:14653-
25 61). The monoclonal antibody FN18 is the monkey equivalent of the human anti-CD3 (UCHT1) and is known to bind the same CD3 receptor epitopes (ϵ and γ) as bound by the human CD3 antibody and is the same isotype as the human CD3 antibody. Thus, in terms of the parameters
30 relevant for predicting successful T cell depletion, the present CD3-CRM9 conjugate and FN18-CRM9 are expected to have the same activity.

Administration.

Conjugates can be administered as an I.V. bolus in a carrier consisting of 0.1M Na_2SO_4 + 0.01M phosphate buffer, pH 7.4 plus 1 part in 50 of serum previously
5 obtained from the subject. The dose schedule is every other or third day for 3 to 6 days. The total dose is preferably from 25 to 200 micrograms of toxin per kg of body weight.

10 The actual dose of FN18-CRM9 used was equal to 0.167 of the minimum lethal dose (MLD) in guinea pigs. Since the estimation of the MLD was performed in an animal lacking an immunotoxin target cell population (guinea
15 pigs), the true MLD of FN18-CRM9 and anti-CD3-CRM9 is expected to be higher in monkeys and humans than in guinea pigs.

T Cell Kill.

Helper T cell (CD4+ cells) numbers in peripheral
20 blood fell dramatically after the initial administration of FN18-CRM9 in two rhesus monkeys. T cell counts began to rise by day 4 (sampled just prior to the second dose of FN18-CRM9). On day 5 in monkey 8629, CD4+ cells were depressed below the limit of detection (<50 cells/ mm^3).
25 Cells remained below or equal to $200/\text{mm}^3$ out to day 21. This low level of CD4+ cells is associated with profound immunodeficiency in humans and in monkeys (Nooij and Jonker (1987) *Eur. J. Immunol.* 17:1089-1093). The
30 remarkable feature of this study is the long duration of helper T cell depletion (day 21) with respect to the last administration of immunotoxin (day 4) since intravenously administered immunotoxins were cleared from the vascular system with half-lives <9 hours (Rostain-Capaillon and

Casellas (1990) *Cancer Research* 50:2909-2916), the effect
outlasting circulating immunotoxin. This is in contrast
to T cell depletion induced by unconjugated anti-CD3
antibodies (Nooij and Jonker (1987) *Eur. J. Immunol.*
5 17:1089-1093).

In monkey 1WS the second dose of conjugate only
appeared to result in a diminished rate of CD4+ cell
recovery. However, CD4+ cells were still fewer than
10 normal at day 21. The blunted response of monkey 1WS to
the second dose of immunotoxin was found to be due to a
preexisting immunization of this animal to the toxin.
Monkey 1WS had a significant pre-treatment anti-diphtheria
toxin titer as revealed by a Western blot assay. This
15 titer was markedly increased at day 5, indicative of a
classic secondary response. In contrast, monkey 8629 had
no detectable pre-treatment titer and only a trace titer
by day 5 and a moderate titer by day 28.

20 The specificity of FN18-CRM9 toward T cells can be
seen by comparing the total white blood cell (WBC) count
in the same two monkeys. WBCs fell, but only to 45% of
baseline value on day 2 compared to 6% of baseline values
for the CD4+ T cell subset. Most of the fall in WBC
25 values can be accounted for by the T cell component of the
WBC population ($\approx 40\%$). However, B cells are initially
depleted after FN18-CRM9 although these cells recover more
quickly. FN18 is an IgG, isotype and as such is known to
bind to FC_{II} receptors present on B cells and macrophages
30 with low affinity. The FN18-CRM9 depletion of B cells
indicates that significant interactions between the Fc
portion of the FN18 antibody and B cells is taking place.

5 The peripheral T cell depletion induced by unconjugated FN18 at a dose known to produce immunosuppression 0.2mg/kg/day (Nooij and Jonker (1987) *Eur. J. Immunol.* 17:1089-1093) was compared to the
10 immunotoxin FN18-CRM9 administered at 1/9th the FN18 dose. Peripheral CD4+ T cell depletion is more pronounced and more long-lasting with the conjugate. The demonstration that FN18-CRM9 reduces peripheral helper T cell subset (CD4+) to levels less than or equal to 200 cell/mm³ for a
15 period as long as 21 days demonstrates that this immunotoxin and its anti-human analogs are effective immunosuppressive reagents.

15 The demonstration that FN18-CRM9 is a potent agent for inducing T cell depletion in non-human primates demonstrates that an anti-human homolog of FN18-CRM9, UCHT1-CRM9 (Oxoid USA, Charlotte, NC) for example, is a potent agent for inducing T cell depletion in humans.

20 The Fc binding region of anti-TCR/CD3 monoclonals may or may not be needed to induce T cell depletion when the anti-TCR/CD3 monoclonals are conjugated to CRM9. The Fc_{II} binding regions can be removed, for example, by forming the conjugates with F(ab')₂ derivatives as is
25 indicated in the literature (Thorpe et al. (1985) *J. Nat'l. Cancer Inst.* 75:151-159). In addition, anti-TCR/CD3 IgA switch variants such as monoclonal antibody T3. A may be used (Ponticelli et al. (1990) *Transplantation* 50:889-892). These avoid rapid vascular
30 clearance characteristic of F(ab')₂ immunotoxins. F(ab')₂ and IgA switch variants of anti-TCR/CD3-CRM9 immunotoxins are therefore derivative anti-TCR/CD3 immunotoxins. These derivatives will avoid the B cell interaction noted and

can increase specificity. However, IgG_{2a} switch variants will maximize T cell activation through the Fc_γ receptor and may be useful in certain situations where T cell activation aids immunotoxin induced toxicity.

5

General methods to make antibodies lacking the Fc region or to make antibodies which are humanized are set forth in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1988. Thus, as used in the claims, antibody can mean the entire antibody or any portion of the antibody sufficient for specific antigen or receptor binding.

EXAMPLE 6

15

Treatment of Autoimmune Diseases Using Other Antibody-CRM9 Conjugates which Route by the Anti-CD3 Pathway

Since receptor recycling is a requirement for effective CRM9 based immunotoxins and since TCR/CD3 recycles as a unit, antibodies directed at other epitopes on TCR/CD3 will constitute effective derivatives, in particular antibodies directed at the approximately 50 Vβ subset families or the approximately equal number Vα subsets can be used to conjugate CRM9 and ablate specific Vβ or Vα subsets *in vivo*. In addition, in some cases it will be desirable to develop specific monoclonal antibodies reacting with unique rearrangements of either the Vα or Vβ subset families.

30

The advantage of targeting the specific Vβ or Vα subset(s) as opposed to the entire T cell population is twofold: (1) Elimination of a Vβ subset does not create a

generalized immunodeficiency, only a hole in the immune repertoire is generated. Therefore, the ability to ward off most infections and maintain immune surveillance of most malignant transformations would remain intact. (2)

5 Immunotoxin log kill increases linearly as the target cell burden decreases, assuming dose is unchanged. A 50-fold increase in log kill can be obtained as the target is changed from the entire set of T cells to a single V β subset. However, due to (1) the high affinity of binding
10 of these immunotoxins, (2) the very low total dose given which is below target cell receptor saturation and (3) the irreversible nature of the endocytotic process, the target cells deplete the effective dose and this depletion decreases as target burden decreases. Since the log kill
15 is exponential in effective dose, much higher increases in log kill than 50-fold on changing the target from T cells to a V β subset can occur. The expected increase in log kill will only occur if the immunotoxin is specific for the defined target. Extraneous interactions with other
20 cell types via the antibody Fc piece is preferably eliminated.

Because HIV has been shown to preferentially infect one (V β_{12}) or a few of the 20 V β subset families providing
25 a small T cell reservoir of HIV replication, and because HIV infection apparently involves an unknown superantigen, CRM9 based immunotoxins directed at these specific V β subsets such as anti-V β_{12} -CRM9 can reduce the HIV virus load. In addition, total ablation of a V β subset in the
30 presence of an endogenous superantigen can lead to long term ablation of the subset since maturing T cells are negatively selected in the presence of endogenous superantigens. Since the specific V β subset responding to

the superantigen is eliminated, infection cannot take place.

5 The two strategies that can be utilized for using anti-V β_{12} -CRM9 immunotoxins to treat HIV infections are (1) treatment depleting the susceptible V β subset to an extent where continued infection cannot be maintained and (2) treatment to the extent that all or nearly all of the V β_{12} subset is eradicated.

10

Anti-human V β monoclonal antibodies such as S5-11 (anti-V β_{12}) are available (T Cell Sciences, Cambridge, MA) and can be conjugated to CRM9 by standard methodologies.

15

Briefly, as in Example 5, conjugation of anti-V β and anti-V α IgG monoclonal antibodies to CRM9 is performed by the same methods used to conjugate anti-CD3 to CRM9 using a non-cleavable linker such as bismaleimido-hexase and previously described in detail (Neville et al. (1988) *J.*

20

of Biol. Chem. 264:14653-61).

25 Conjugates can be administered as an I.V. bolus in a carrier consisting of 0.1M Na₂SO₄ + 0.01M phosphate buffer, pH 7.4 plus 1 part in 50 of serum previously obtained from the patient. The dose schedule is every other or third day for 3 to 6 days. The total dose is preferably from 25 to 200 micrograms of toxin per kg of body weight, but may be increased if anti-diphtheria toxin antibodies are present in the patient's sera in significant amounts.

30

Other V β or V α subsets which may be found to be associated with HIV infection can be treated in the same manner described herein by conjugating the CRM9 to the

antibody specifically reactive with the appropriate V β or V α subset.

EXAMPLE 7

5

**T Cell Depletion and Immunosuppression in Monkeys Using
the Immunotoxin Anti-CD3-CRM9.**

CRM9 is a diphtheria toxin (DT) binding site mutant
10 and forms the basis of the anti-T cell immunotoxin anti-
CD3-CRM9. This immunotoxin has been constructed against
human and rhesus T cells and has shown above to kill 3
logs of human T cells in a nude mouse xenograft system.
The present example demonstrates a 2 log kill of T cells
15 in rhesus monkey lymph nodes that is also shown to produce
prolongation of skin allograft rejection in monkeys.

Humans are immunized against diphtheria toxin by
exposure to DPT vaccines in childhood. This long lasting
20 immunity may interfere with the efficacy of DT based
immunotoxins. Many monkeys are immunized against DT by
natural exposure to toxin producing Corynebacterium. The
present method addresses any potential interference of
pre-existing DT antibodies with the activity of the
25 present immunotoxins.

ELISA

ELISA assays were performed in order to determine the
levels of anti-DT titers existing in 9 individuals in a
30 population ages 27 to 55. There were 3 individuals with
titers of 1:100 (low) and 6 with titers of 1:1000
(moderate).

Rhesus monkeys were screened by the same assay and a 1:1000 titered monkey was selected.

Administration of Non-Toxic Diphtheria Toxin Mutant.

5 Monkeys were treated by I.V. route 5 min prior to the immunotoxin dose with a 100 fold excess of CRM197 over the CRM9 content of the immunotoxin to be administered. Just prior to administering CRM197, a H1 histamine blocking agent such as Benadryl or Tavegil was given I.V. to
10 minimize any possibility of an anaphylactic reaction (for Benadryl 4 mg/kg). No histaminic reaction was detected.

Anti-CD3-CRM9 was given at a total dose between 0.1 and 0.2 mg/kg (toxin weight) in 3 equally divided doses
15 (approximately 0.033 mg/kg) on 3 consecutive days. In these monkeys, the total dose of immunotoxin was 0.1 mg/kg.

Table 1 shows a comparison of the efficacy of anti-
20 CD3-CRM9 in monkeys by comparing the decrease in the lymph node T/B cell ratio (a measure of lymph node T cell depletion) and the immunosuppressive effect of the immunotoxin as judged by prolongation of mismatched skin graft survival. Effects on the survival of skin grafts is
25 a clear indicator of the general effect a given treatment has on the subject's immune system.

The monkey with the preexisting anti-DT titer that was pretreated with CRM197 shows the same level of T/B
30 cell inversion as in the negative titered monkey. Skin graft survival was significantly prolonged over the titered monkey treated without CRM197. The failure to achieve a prolongation of graft survival equal to the

negatively titrated monkey is likely due to the lower weight of this monkey which causes T cells to repopulate faster, in this case 3-4 days faster, due to the larger thymic T cell precursor pool in younger animals. Age related effects such as these can be compensated for by modification of dosage levels and timing of administration.

ATTORNEY DOCKET NO. 14014.0225

TABLE 2. Efficacy of Anti-CD3-CRM9 With and Without CRM197 In Rhesus Monkeys
With Positive and Negative Anti-Diphtheria Toxin Titers.

Monkey	Weight kg	Anti-DT Titer	Treatment	Post Treatment*		Day(s) of Skin Graft Survival
				Lymph node T/B Cell Ratio		
historical controls	4-7	N/A	None	2.1-2.4 ⁺		9.5±08 ^s
B65	5.1	neg	anti-CD3	1.8		12, 12
8838	5.1	neg	anti-CD3-CRM9	0.14 ^{xx}		19, 20
M93	5.1	1:1000	anti-CD3-CRM9	0.57		11, 12
C81	1.0	1:1000	CRM197 + anti-CD3-CRM9	0.20		14, 15

* All monkeys received the same dose of immunotoxin 0.1 mg/kg total in divided doses on day 0, 1 and 2. Lymph node sampled on day 3. CRM197 when given in 100 fold excess over CRM9 content.

+ In this study untreated animals show this lymph node T/B ratio

\$ Historical controls at TNO, Rijswijk

xx Anti-CD3 given at the same mol. dose as anti-CD3-CRM9

EXAMPLE 8

**Immunotoxin UCHT1-CRM9 for the Treatment of Steroid
Resistant Graft-Versus-Host Disease**

5

Treatment protocols for this type of disease can be expected to last a year, with Patients being followed for at least 5 years.

10 **Characterization of UCHT1-CRM9 and CRM197.**

UCHT1-CRM9 is a covalent 1:1 conjugate of anti-human CD3 IgG1 monoclonal antibody and CRM9. The conjugate is synthesized, purified, sterile filtered and assayed for concentration, biological efficacy toward target cells and
15 non-target cell toxicity by standardized culture assays. The method of synthesis, purification assay are identical to that used for FN18-CRM9 which was used in the pre-clinical monkey studies described in Examples 5 - 7.

20 CRM9 and CRM197 are produced by the Biotechnology Unit, NIH and purified by the Cooperating Facility. UCHT1 is produced in mouse ascites fluid and is purified by affinity chromatography over Protein A Sepharose. The synthesis, purification and storage of UCHT1-CRM9 is
25 performed in a dedicated secure area. UCHT1-CRM9 is purified in 2 mg lots which are pooled and stored at 4°C. Shelf life is documented to be five months at full biological potency but does not exceed 4 months for this study. Preferably, most of the immunotoxin is used within
30 3 months of synthesis.

10

15

UCHT1-CRM9 is administered at a dose which is 1/10 or less of the estimated minimum lethal dose (MLD) in a T lymphopenic patient. The MLD is expected to be at least 0.15 mg/kg (CRM9 content) based on the MLD of 0.15 mg/kg of IgG1-CRM9 in guinea pigs which lack a target cell population for the IgG1. (The presence of target cells in humans raises the MLD by providing a sink for the immunotoxin.) The optimal dose schedule has been found in monkeys to be administration on 3 consecutive days in 3 equally divided doses, and this schedule can be used throughout the treatment period. This permits administration of the total dose before any rise in pre-existing antitoxin titers due to a secondary response. In addition, the initial repopulation from the thymus is also eliminated, thus, further lowering the total T lymphocyte pool. Therefore, a total of 0.0125 mg/kg in three equally divided doses is given to the patient. This dose does induces T cell depletion in monkeys so that monitoring of T cell subsets and signs and symptoms of GVHD is relevant at the lowest dose. For the administration of this dose patients with anti-CRM9 titers of 1:100 or less will be treated. This permits

ATTORNEY DOCKET NO. 14014.0225

pretreatment doses of CRM197 at 0.33 mg/kg or 1/10 the dose easily tolerated in monkeys. A second dosage group can include patients selected for antitoxin titers of 1:330 or less to whom CRM197 will be given at 1.0 mg/kg.

5 A third dosage group can include patients with 1:1000 antitoxin titers or less will be given CRM197 at 3.3 mg/kg, a dose expected to be tolerable in humans, because it is easily tolerated by monkeys (see Example 7). The monkey MLD data should be very similar to humans on a per

10 weight basis. However, GVHD patients are expected to be more like guinea pigs, because they have a smaller target cell population compared to non-GVHD patients.

Dose escalation can be tested by increasing the dose

15 by a factor of 1.5. The following table exemplifies such a dose escalation test. For example three patients are used in each dosage group. There is a 3 to 4 week delay between each patient so that any late toxicity is detected before a dosage group is completed:

20

Patient #	CRM9 Dose each day mg/kg	Total Dose mg/kg	Week ending
1,2,3	0.00417	0.0125	12
4,5,6	0.00636	0.019	24
7,8,9	0.0083	0.028	36
10,11,12	0.0125	0.042	48

Assuming each patient weighs on the average 70 kg, the first dosage group will consume 2.6 mg of the CRM9 immunotoxin, and will be supplied as a pool of two 2 mg batches. The second group will consume 3.9 mg and will

5 also be supplied as 2 pooled batches. The third group

will require 5.9 mg and will be supplied as three pooled batches. The fourth group will require 8.9 mg and will be supplied as three pooled batches and an additional two pooled batches.

5

Administration.

Prior to administering CRM197 a H1 histamine blocking agent such as Benadryl or Tavegil is given I.V. to minimize any possibility of an anaphylactic reaction (for
10 Benadryl 4 mg/kg). The CRM197 is administered I.V. in a 5 mg/ml sterile filtered solution in phosphate buffered saline pH 7.4 (PBS) over a 5 min time period. The immunotoxin is then given I.V. at 0.2 mg/ml over 2 min time period in a sterile filtered solution of 0.90mM
15 sodium sulfate and 10mM sodium phosphate pH 7.4.

Measurements of Biological Parameters.

The following parameters can be measured at various intervals during treatment (as exemplified by the schedule
20 below):

- A Cytokines, TNF alpha, gamma IFN, IL-6
- B Routine clinical chemistries
- C WBC, Hct, diff; lymphocyte subsets CD3, CD4, CD8, CD2, CD16, CD20
- 25 D Body Weight
- E Immune function assays. ELISA assays of serum to monitor antibody responses to UCHT1 (primary response) and CRM9 (secondary response). ELISA assays to monitor antibody responses to polio and DPT reimmunizations done
30 at 1 year following bone marrow transplantation.

(before IT) Day 0	A, B, C, D, E	Also A 2 hrs post
Day 1	A, C, D	

Day 2 A, C, D
Day 3 A, B, C, D
Day 4 C, D
Day 7 A, C, D
5 Day 10 B, C
Day 14 A, C, D
Day 21 C, D
Day 28 A, B, C, D, E
Day 45 C, D
10 Day 60, B, C, D, E

EXAMPLE 9

15 **An anti-CD3 single-chain immunotoxin with a truncated
diphtheria toxin avoids inhibition by pre-existing
antibodies in human blood**

The present Example examines the effect of human
20 serum with pre-existing anti-DT antibodies on the toxicity
of UCHT1-CRM9, an immunotoxin directed against CD3
molecules on T-lymphocytes. Sera with detectable anti-DT
antibodies at 1:100 or greater dilutions inhibited the
immunotoxin toxicity. Experiments with
25 radiolabeled-UCHT1-CRM9 indicate that anti-DT antibodies
partially block its binding to the cell surface as well as
inhibit the translocation from the endosome to the
cytosol. The inhibitory effect could be adsorbed using a
full-length DT mutant or B-subfragment. A C-terminal
30 truncation mutant could not adsorb the inhibitory effect,
suggesting that the last 150 amino acids contain the
epitope(s) recognized by the inhibitory antibodies.

Therefore, an anti-CD3 single-chain immunotoxin, sFv-DT390, was made with a truncated DT. The IC_{50} of sFv-DT390 was 4.8×10^{-11} M, 1/16 the potency of the divalent UCHT1-CRM9. More importantly, sFv-DT390 toxicity
5 was only slightly affected by the anti-DT antibodies in human sera. "sFv" and "scUCHT1" both are single chain antibodies containing the variable region.

10 Mutated full-length and truncated diphtheria toxin (DT) molecules are used for making immunotoxins. These immunotoxins show strong cytotoxic effects to their target cells, and some of them have already been used in clinical trials (1-7).] Previously, an immunotoxin directed against the CD3 ϵ molecule of the T-cell receptor complex, a pan
15 T-cell marker was constructed. This construct is made with a monoclonal antibody of mouse-origin, UCHT1, and a binding site mutant of diphtheria toxin (DT), CRM9 (8). The immunotoxin, UCHT1-CRM9, is capable of regressing established xenografted human T-cell (Jurkat) tumors in
20 nude mice (9). A rhesus monkey analog of UCHT1-CRM9, FN18-CRM9 was capable of not only depleting circulating T-cells but also depleting resident T-cells in the lymph nodes. This immunotoxin also delayed skin allograft rejection as compared to antibody treatment and
25 non-treatment controls.

In contrast with ricin and *Pseudomonas* exotoxin (PE) based immunotoxins, there is a potential problem using UCHT1-CRM9, or other DT-based immunotoxins, in the
30 treatment of human diseases. Most people have been immunized against DT. Therefore these people have a pre-existing anti-DT antibody titer which could potentially inhibit or alter the efficacy of these

immunotoxins. This limitation also occurred in rhesus monkey studies. FN18-CRM9 could deplete T cells in the blood, but to a much lesser extent in animals with anti-DT antibodies, and the T cells repopulated several days
5 earlier compared to those monkeys without anti-DT titers. In order to overcome this antibody mediated inhibition, the first examination of the effect and the mechanism of human sera containing anti-DT antibodies on UCHT1-CRM9 toxicity was done.

10

A DT point-mutant, a truncation mutant and DT-subfragments were used in an attempt to neutralize the anti-DT effect in human sera. Based on the neutralization data, a single-chain immunotoxin was constructed with a
15 C-terminal deletion mutant of DT which is expected to bypass the inhibitory effect of the pre-existing anti-DT antibodies.

Cells.

20 Jurkat cells (ATCC) were maintained in RPMI 1640 supplemented with 10% fetal calf serum, 25 mM sodium bicarbonate and 50 µg/ml of gentamycin sulfate.

Serum and adsorbing molecules.

25 Goat anti-DT serum was provided by Dr Randall K. Holmes (USUHS, Bethesda, MD). Human serum samples were provided by Dr. Henry McFarland (NINDS, NIH, Bethesda MD). CRM197, an A-subfragment mutant (Gly 52 to Glu) of DT (see Figure 2A), with no enzymatic activity (10) is available
30 from Biocine-IRIS (Siena, Italy). MSPA5, a truncation mutant (amino acid 385) of DT with an additional 5 amino acids at the C-terminus was provided by Dr. Richard Youle (NINDS, NIH, Bethesda MD). Purification of the DT

B-subfragment has been described (11). Immunotoxins-
UCHT1-CRM9 synthesis has been described (12).

00334695-002500
The recombinant immunotoxin, sFv-DT390, was generated
5 in two phases. First the coding sequences for the
variable light (V_L) and variable heavy (V_H) chain regions
of the UCHT1 antibody were amplified by a two step
protocol of RT-PCR using primers based on the published
sequence (13). The 5' V_L primer added a unique NcoI
10 restriction enzyme site while the 3' V_H primer added a
termination codon at the J to constant region junction and
an EcoRI site. The V_L region was joined to the V_H region
by single-stranded overlap extension and the two regions
are separated by a $(Gly_3Ser)_4$ linker that should allow for
15 proper folding of the individual variable domains to form
a function antibody binding site (14). Second, genomic
DNA was isolated from a strain of *C. diphtheriae* producing
the DT mutant CRM9 (C7[$\beta^{htox-201tox-9h}$]) as described (15).
This DNA was used for PCR. The 5' primer was specific for
20 the toxin gene beginning at the signal sequence and added
a unique NdeI restriction site. The 3' primer was specific
for the DT sequence terminating at amino acid 390 and
added an NcoI site in frame with the coding sequence. The
PCR products were digested with the appropriate
25 restriction enzymes and cloned into the *E. coli* expression
plasmid pET-17b (Novagen, Inc., Madison, WI, USA) which
had been linearized with NdeI and EcoRI. The resulting
plasmid was used to transformed *E. coli* BL21/DE3 cells.
Cells were grown to an OD_{590} of 0.5, induced with 0.5 M
30 IPTG (Invitrogen, San Diego, CA, USA) and incubated for an
additional 3 hours. The sFv-DT390 protein was isolated in
the soluble fraction after cells were broken with a French

Press and the lysate subjected to centrifugation at 35,000 X g.

Protein synthesis inhibition assay.

5 Inhibition assays were performed as described (12) with the following modifications. Immunotoxins were incubated for 30 minutes with the indicated serum sample or leucine free medium at room temperature prior to addition to cells. In some experiments the serum was
10 pre-incubated for 30 minutes with an adsorbing molecule at the given concentrations to bind the antibodies. The immunotoxin/serum mixture was incubated with Jurkat cells (5×10^4 cells/well in 96 well plate) for 20 hours. A 1 hour pulse of [3 H]-leucine ($4.5 \mu\text{Ci/ml}$) was given before
15 cells were collected onto filters with a Skatron harvester. Samples were counted in a Beckman scintillation counter. Each experiment was performed in 4 replicates. Results were calculated into a mean value, and recorded as a percentage of control cells.

20

Serum antibody detection.

 Anti-DT antibodies were detected in human serum by ELISA. CRM9 ($10 \mu\text{g/ml}$) was adsorbed to Costar 96-well EIA/RIA flat bottom plates (Costar, Cambridge, MA, USA)
25 for 2 hours and then washed in phosphate buffered saline (PBS) containing 0.1% Tween 20. Each well was then incubated with PBS containing 3% gelatin to prevent non-specific binding of antibodies to the plastic. Serum samples were diluted in PBS containing 0.1% Tween 20 and
30 0.3% gelatin prior to addition to the plate. After 1 hour incubation, the wells were washed as above, and incubated for an additional hour with protein A/G-alkaline phosphatase (1:5,000; Pierce, Rockford, IL, USA). Wells

were washed, and phosphatase substrate (Pierce) was added following the manufacturer's directions. After 30 minutes color development was stopped with NaOH and the optical density (OD) was measured with a kinetic microplate reader (Molecular Devices Corporation, Palo Alto, CA, USA). Each sample was performed in triplicate. Results are presented as O.D. values and antibody titers.

Endocytosis assay.

10 UCHT1-CRM9 was iodinated using the Bolton-Hunter reagent (NEN Dupont, Wilmington, DE, USA) as described (16). Jurkat cells were washed twice with binding medium (RPMI 1640 supplemented with 0.2% bovine serum albumin, 10 mM Hepes (pH 7.4) and without sodium bicarbonate). Cells
15 (1.5×10^6) were incubated for 2 hours on ice with ^{125}I -UCHT1-CRM9 (1×10^{-9} M) that had been pre-incubated with serum or binding medium. Unbound antibody was removed by washing the cells twice in PBS (pH 7.4) with centrifugation and resuspension. Duplicate samples were
20 incubated for 30 minutes on ice or at 37°C. One sample from each temperature point was centrifuged at 800 x g to separate the total cell associated (pellet) from the exocytosed or dissociated counts (supernatant). Both fractions were counted in a Beckman a γ -counter. To
25 determine the amount of internalized immunotoxin, cells from the second sample at each temperature were incubated in low pH medium (binding medium containing 10 mM morpholinoethanesulfonic acid, all of which was titrated to pH 2.0 with HCl) for 5 minutes to dissociate the
30 surface bound ^{125}I -immunotoxin (17). Samples were centrifuged at 800 x g to separate the internalized (pellet) from the membrane bound (supernatant). Both

ATTORNEY DOCKET NO. 14014.0225

fractions were counted in a Beckman γ -counter (Beckman, Fullerton, CA, USA).

Serum with anti-DT antibodies inhibits UCHT1-CRM9

5 toxicity.

Since humans are immunized against DT, the presence of anti-DT antibodies in the serum was determined by ELISA (Table 3). In a limited sample population, 80% of the serum samples had an anti-DT antibody titer of 1:100 or
10 above. The vaccination status of the donors was not available. To determine the effect of these antibodies on UCHT1-CRM9 toxicity, the immunotoxin was pre-incubated with different concentrations of serum and the toxicity of the mixture was assayed (Table 3). Serum samples without
15 a significant ELISA O.D. (2 fold above background) were incapable of affecting UCHT1-CRM9 toxicity at high concentrations of serum (1:10). However, serum samples with a positive ELISA result could neutralize the cytotoxic effect at 1:10 dilution, and those with a high
20 ELISA O.D. (7-11 fold above background) inhibited toxicity even at a 1:100 dilution. Similar results were seen in assays conducted with monkey serum samples.

ATTORNEY DOCKET NO. 14014.0225

Table 3. Human serum with anti-DT antibodies inhibits the toxicity of UCHT1-CRM9 and the inhibition correlates with the anti-DT titer

Sample	ELISA		Protein Synthesis ^b (% control)		
	O.C. (X ± S.D.)	Titer	1:10	1:100	1:1,000
10010	0.738 ± 0.017	1:750	97 ± 3	79 ± 8	2 ± 0
10011	0.568 ± 0.048	1:500	104 ±	13 ± 2	2 ± 0
10012	0.491 ± 0.025	ND ^c	96 ± 3	19 ± 2	2 ± 0
10013	0.411 ± 0.052	1:500	105 ± 8	7 ± 1	2 ± 0
10014	0.390 ± 0.047	1:500	96 ± 2	7 ± 0	2 ± 0
10015	0.353 ± 0.008	1:250	125 ± 6	6 ± 4	2 ± 0
10019	0.359 ± 0.019	1:250	101 ± 7	6 ± 1	2 ± 0
10016	0.141 ± 0.015	1:100	22 ± 1	3 ± 0	2 ± 0
10017	0.100 ± 0.006	<1:100	4 ± 0	3 ± 0	2 ± 0
10018	0.071 ± 0.001	<1:100	2 ± 0	2 ± 0	2 ± 0
Goat	1.450 ± 0.013	1:10 ⁵		102 ± 19	104 ± 3

^aELISA was performed in triplicate for each serum sample as described under "Materials and Methods." The O.D. values were derived from 1:100 dilutions and presented as a mean value ± SD. The background value was 0.060 ± 0.02. titers are recorded as the highest serum dilution that showed a positive reaction in ELISA.

^bUCHT1-CRM9 (2 x 10⁻¹⁰) was incubated with different dilutions of serum for 30 min. The mixture was then added to cells as described under "Materials and Methods." Four replicates were performed for each sample. Data are presented as a mean value ± S.C. in percentage of the control counts. UCHT1-CRM9 inhibited protein synthesis to 2.0% of controls. The goat anti-DT serum could be diluted to 1:10,000 and still completely inhibited the toxicity of UCHT1-CRM9.

^cND, not done

Sera do not inhibit endocytosis of UCHT1-CRM9.

The inhibitory effect of serum on UCHT1-CRM9 toxicity could be due to prevention of the immunotoxin binding to the cell surface or the endocytosis of UCHT1-CRM9 into the cell. Endocytosis assays were conducted using ¹²⁵I-UCHT1-CRM9 to determine if either of these processes were affected by anti-DT antibodies present in sera. The results indicate that the presence of serum (goat anti-DT or human) reduces as much as 80% of the immunotoxin counts binding to the cell surface (Table 4). While this is a significant reduction in binding, limiting 90% of input immunotoxin (one log less UCHT1-CRM9) in toxicity assays reduces protein synthesis to <25% of controls (see Figure 3). In contrast, the inhibitory effect of serum containing anti-DT antibodies is 100%. Therefore the effect of the anti-DT antibodies is not all at the level of inhibition of binding to the cell surface. The pre-incubation of ¹²⁵I-UCHT1-CRM9 for 2 hours on ice and subsequent washing at room temperature resulted in 18 to 25% of the total cell associated counts internalized (Table 4). After incubation for 30 minutes at 37°C, there is a doubling of internalized counts both with and without serum, indicating that the same percentage of labeled immunotoxin is endocytosed. The identical dilutions of serum were incubated with non-labeled UCHT1-CRM9 and used in protein synthesis inhibition assays. The results demonstrate that the ratio of immunotoxin to serum used was capable of completely inhibiting the toxicity (Table 4), although the endocytosis of UCHT1-CRM9 was not affected.

ATTORNEY DOCKET NO. 14014.0225

Table 4. Inhibition of UCHT1-CRM9 toxicity by serum does not correlate with inhibition of endocytosis.

Serum Sample	Time (37°C)	% Bound	% of Bound internalized	Protein Synthesis (% Control)
-	0	100	23.6.	N.D. ^a
-	30	100	58.8	3 ± 1
Human	0	20	18.1	N.D. ^a
Human	30	19	35.9	105 ± 5
-	0	100	25.3	N.D. ^a
-	30	100	54.0	3 ± 1
Goat	0	37	24.4	N.D. ^a
Goat	30	33	50.7	92 ± 14

[¹²⁵I]-UCHT1-CRM9 (2 x 10⁻⁹ M) was incubated with medium or anti-DT serum (1:4 dilution of human sample 10010 or a 1:1,000 dilution of goat serum; Table 3) for 30 minutes at room temperature. This mixture was added to Jurkat cells (1.5 x 10⁶) for 2 hours on ice (final concentration of [¹²⁵I]-UCHT1-CRM9 was 1 x 10⁻¹⁰). The cells were then washed and endocytosis assays performed as described in Materials and Methods. The % Bound value represents the cell associated counts divided by the cell associated counts divided by the cell associated counts above dilutions of sera and the resulting mixture was used in protein synthesis inhibition assays. the results shown are representative of two independent assays.

n.d.: not done.

The inhibitory effect of anti-DT antibodies can be removed by adsorption.

To prevent the inhibitory effect of serum as well as gain insight into the mechanism by which serum inhibits toxicity, experiments were designed to adsorb the protective anti-DT antibodies from the serum. The serum (a pool of all human sera with positive anti-DT ELISA or goat anti-DT) was pre-incubated for 30 minutes with increasing concentrations of CRM197 (an A-chain mutant of DT with no enzymatic activity), MSPA5 (a truncation mutant missing the last 150 amino acids) and the purified A- and B-subfragments of DT (Figure 2A). The adsorbed serum was then incubated with UCHT1-CRM9 in protein synthesis inhibition assays. CRM197, the full length DT-like construct, was capable of completely adsorbing the protective antibodies from both goat (Figure 2B) and pooled human serum (Figure 2C). The B-subfragment of DT is also capable of complete adsorption, however ~100 fold more is required. The A-subfragment of DT had little or no effect on either serum, although the serum samples were demonstrated to contain antibodies reactive to both the A- and the B-subfragments by Western Blot analysis. Of interest were the results seen with MSPA5, the truncation mutant. Adsorption of goat serum with MSPA5 gave a dose dependent removal of the serum's protecting effect (Figure 2B). However, this adsorption could not bring toxicity down to levels obtained when CRM197 or the B-subfragment was used.

In contrast to the results observed with the goat serum, MSPA5 had little effect on pooled human serum (Figure 2C). These results suggest that the pre-existing anti-DT antibodies important for the protecting effect in

human serum are mainly directed against the last 150 amino acids of DT.

sFv-DT390 is not inhibited by anti-DT antibodies present
5 **in human sera.**

Having observed that the epitope(s) recognized by the antibodies important for protection lay in the C-terminal 150 amino acids, a single-chain immunotoxin was generated with the first 390 amino acids (out of 535) of DT.

10 Position 390 was chosen for 2 reasons: first, the 3 dimensional structure of DT suggested that this position was an external point on the molecule away from the enzymatic domain (18), and second, fusion toxins have been generated with longer DT subfragments with no reports of

15 serum effects (19). The DNA encoding the first 390 amino acids of DT was ligated to DNA encoding the anti-CD3esFv (V_L linked to V_H using a $(Gly_3Ser)_4$ linker sequence). The predicted molecular weight for the fusion protein is 71,000 Daltons and has been confirmed by Western Blot

20 analysis of both *in vitro* transcribed and translated protein as well as protein isolated from *E. coli* using goat anti-DT antibodies. The toxicity of sFv-DT390 protein, isolated from *E. coli* strain BL21/DE3, was compared to UCHT1-CRM9 in protein synthesis inhibition

25 assays (Figure 3A). The IC_{50} (concentration required to inhibit protein synthesis to 50% of controls) of sFv-DT390 was 4.8×10^{-11} M compared to 2.9×10^{-12} M for UCHT1-CRM9, a 16-fold difference. To demonstrate the specificity of the sFv-DT390 construct, competition experiments were

30 performed using increasing concentrations of UCHT1 antibody as competitor (Figure 3B). The results showed that approximately 1/8 antibody is needed to compete the sFv-DT390 toxicity to 50% as compared to UCHT1-CRM9. The

antibody was capable of totally competing toxicity of both constructs thereby showing their specificity. The immunotoxins were then subjected to protein synthesis assays in the presence of increasing dilutions of serum
5 (Table 5).

UCHT1-CRM9 toxicity was completely inhibited with a 1:10 dilution of the human sera but at a 1:100 dilution toxicity was equivalent to controls without serum. In
10 contrast, the sFv-DT390 immunotoxin is only partially inhibited with the 1:10 dilution of the human sera and the 1:100 dilution no effect on the toxicity. Both immunotoxins are completely inhibited by goat anti-DT serum (1:1,000 dilution). These results indicate that the
15 sFv-DT390 immunotoxin partially evades the pre-existing anti-DT antibodies present in most human sera.

These results indicate that the pre-existing anti-DT antibodies present in human serum inhibit the toxicity of
20 the immunotoxin UCHT1-CRM9. This inhibition of toxicity was also observed with goat anti-DT serum, however less goat serum was needed to completely inhibit toxicity. The experiments were designed in such a way to mimic the *in vivo* situation. The peak concentration of circulating
25 immunotoxin currently being tested in animal models is 1×10^{-9} M. The immunotoxin concentration incubated with the 1:10 dilution of human serum was 1×10^{-10} M, thus approximating *in vivo* conditions. The inhibition of toxicity correlates with the serum antibody levels as
30 determined by ELISA (Table 4), indicating that sera with higher anti-DT titers have a stronger inhibitory effect. Similarly, the goat anti-DT serum which gave the highest ELISA value could be diluted 10,000 times and still

completely inhibited UCHT1-CRM9 toxicity. Since this correlation exists, there is no indication that any other component of the serum inhibits the toxicity of UCHT1-CRM9.

5

Furthermore, the data show that a titer of 1:100 dilution is necessary for an inhibition of the immunotoxin toxicity. A construct in which the first 486 amino acids of DT were fused to interleukin-2, DAB₄₈₆IL-2, was used in lymphoid malignancy patients. A partial response to DAB₄₈₆IL-2 was observed in several patients who had a anti-DT titer below 1:100 dilution prior to the treatment.

Intoxication of cells by immunotoxins can be subdivided into four general stages: 1) specific binding to the cell surface, 2) endocytosis into the cell, 3) translocation of enzymatic domain of the toxin out of the endosome and 4) enzymatic inactivation of the target molecule. The results presented indicate that, while the amount of immunotoxin reaching the cell surface is lower in the presence of serum, the same percentage of bound immunotoxin is endocytosed. Taking into account the reduced amount of immunotoxin bound to the cell, the amount of endocytosed immunotoxin should intoxicate the cells to below 25% of controls. However, the immunotoxin had no effect on protein synthesis in the presence of serum containing anti-DT antibodies. Since the A-subfragment of DT could not adsorb the protective effect of serum while the B-subfragment could, the effect of serum is not likely to be at the level of inhibiting enzymatic activity of the toxin. Therefore, the anti-DT antibodies probably affect the translocation of the A-subfragment into the cytosol.

CRM197, B-subfragment, and MSPA5 could adsorb the protecting anti-DT antibodies from the goat and rhesus monkey sera. However, among the 3 DT mutants, MSPA5 could not prevent the UCHT1-CRM9 toxicity in the presence of the human sera, showing a difference in the anti-DT antibody repertoire among humans, goat and rhesus monkeys. This difference does not seem to be due to immunization routes, because monkeys used in the present study were not immunized for DT and presumably acquire the antibodies after a natural infection with toxigenic strains of *C. diphtheriae*. There have been reports showing that rhesus monkeys and humans shared a similar antibody repertoire (21), but the present results suggest that the effect of antibodies from the host for whom immunotoxin treatment is intended should be useful.

To overcome the blocking effect of the pre-existing anti-DT antibodies in human sera, there are basically two pathways existing. One is to neutralize the antibodies with non-toxic DT mutants, and the other is to modify the DT structure used for making immunotoxin (3). The antibody neutralization pathway has been tested in monkey studies of FN18-CRM9 treatment as described above.

The present results showed that although antibodies against both A- and B-subfragments existed in human sera, MSP5 could not neutralize the pre-existing protective anti-DT antibodies, and therefore could not prevent the inhibition of the cytotoxicity of UCHT1-CRM9. However, it did block the inhibitory effect of the goat and monkey sera. This prompted the construction of the present recombinant immunotoxin, sFv-DT390. The IC_{50} of sFv-DT390 is 4.8×10^{-11} M, 1/16 as potent as UCHT1-CRM9. Like many

other single-chain constructs, sFv-DT390 is monovalent as compared to immunotoxins generated with full length, bivalent antibodies. The reduced toxicity in sFv-DT390 could be explained primarily on this affinity difference.

5 Immunotoxins generated with purified F(ab)' fragments of antibodies also show an *in vitro* loss in toxicity (generally a 1.5 log difference) when compared to their counterparts generated with full length antibodies (22). The toxicity of sFv-DT390 is comparable to that reported

10 for DAB486IL-2 (23). From the present data some advantages of sFv-DT390 are expected. First, sFv-DT390 is only 1/3 of the molecular weight of UCHT1-CRM9. The molar concentration of sFv-DT390 will be 3 times higher than that of UCHT1-CRM9 if the same amount is given (for

15 example, 0.2 mg/kg). Therefore, their difference in potency could be reduced to approximately 5 times. Second, in an *in vitro* experiment (Table 5), the same molar concentration of sFv-DT390 and UCHT1-CRM9 was used for serum inhibition test, although the former is only

20 1/16-potent compared to the latter. The pre-existing anti-DT antibodies in human sera could only partially block the toxicity of sFv-DT390 while the effect of UCHT1-CRM9 was completely blocked. Thus, sFv-DT390 is expected to bypass the anti-DT antibodies in *in vivo*

25 situations while UCHT1-CRM9 cannot. Third, sFv-DT390 contains only the variable region of UCHT1, and is expected to have less immunogenicity in human anti-mouse antibody (HAMA) responses than the native murine antibody UCHT1. Finally, the production cost of sFv-DT390 is much

30 lower than that of UCHT1-CRM9. Based on these reasons, sFv-DT390, or others with similar properties, are expected to be useful in the treatment of T-cell mediated diseases in humans, especially in anti-DT positive individuals and

ATTORNEY DOCKET NO. 14014.0225

in patients who need repeated treatments. To obtain evidence supporting this assumption, it is only necessary to construct a rhesus monkey analog of sFv-DT390, and test it in monkey models as described in previous examples.

ATTORNEY DOCKET NO. 14014.0225

Table 5: Anti-DT antibodies present in human sera have reduced effect on sFv-DT390 toxicity.

Serum Sample	ELISA value (\pm S.D.)	Protein synthesis (% Control)			
		UchT1CRM9		sFv-DT390	
		1:10	1:10 ²	1:10 ³	1:10 ⁴
10012	0.491 \pm 0.025	119 \pm 24	8 \pm 2	ND*	21 \pm 8
Pooled	0.331 \pm 0.015	108 \pm 37	7 \pm 1	ND*	16 \pm 7
Goat	1.450 \pm 0.013	ND	ND	94 \pm 21	ND
					8 \pm 11

*Not done

UCHT1CRM9 or sFv-DT390 (2×10^{-9} M) was incubated with the indicated dilutions of serum for 30 min. The mixture was then added to cells as described under "Materials and Methods." The final concentration of immunotoxin on cells was 1×10^{-10} M. Four replicates were performed for each sample. Data are presented as a mean value \pm S.D. in percentage of the control counts. UCHT1-CRM9 inhibited protein synthesis to 5% of controls while the sFv-DT390 inhibited protein synthesis to 18% of controls. The ELISA value was determined using a 1:100 dilution of serum. The results are representative of two independent experiments.

EXAMPLE 10

**Expression and Characterization of A Divalent Chimeric
Anti-human CD3 Single Chain Antibody**

5

Murine anti-CD3 monoclonal antibodies (mAbs) are used in clinical practice for immunosuppression. However, there are two major drawbacks of this treatment: the associated cytokine release syndrome and human anti-mouse antibody response. To overcome these side effects, a chimeric anti-human CD3 single chain antibody, scUCHT1 was generated. It is an IgM variant of the UCHT1 described in Example 9. scUCHT1 consists of the light and heavy variable chain binding domains of UCHT1 and a human IgM Fc region (CH₂ to CH₄). The method used was reported by Shu et al. [37] and is further described below. The following data show that the engineered chimeric anti-CD3 single chain antibody (scUCHT1) will be useful in clinical immunosuppressive treatment.

20

Oligonucleotide primers and DNA amplification.

Primers used for the antibody engineering are listed in Table 6, and the primer sequences are based on published data [13]. The procedures of cloning scUCHT1 is schematically depicted in Fig. 4. mRNA isolated from UCHT1 hybridoma cells (provided by Dr. P. C. Beverley, Imperial Cancer Research Fund, London) was reverse transcribed into cDNA. The V_L and V_H regions of UCHT1 were amplified with polymerase chain reaction (PCR) from the cDNA using primer pairs P1, P2 and P3, P4 respectively. Primers P2 and P3 have a 25 bp complementary overlap and each encoded a part of a linker peptide (Gly₄Ser)₃. The single chain variable fragment (V_L-linker-V_H) was created

ATTORNEY DOCKET NO. 14014.0225

by recombinant amplification of V_L and V_H using primers P1 and P4. A mouse kappa chain signal sequence was added at the V_L 5'-end by PCR, first with primers SP2 and P4, and then with primers SP1 and P4. The human IgM Fc region (CH₂ to CH₄) was amplified from the plasmid pBlue-huIgM (kindly provided by Dr. S. V. S. Kashmiri, National Cancer Institute, Bethesda. This gene fragment was about 1.8 kb. The V_L -linker- V_H -CH₂ region which is important for antigen recognition was confirmed by sequence analysis. Finally, the single chain variable fragment and the human IgM Fc region were cloned into plasmid pBK/CMV (Stratagene, La Jolla, CA, USA). Using the generated pBK/scUCHT1 plasmid as template, an *in vitro* transcription-translation assay yielded a product of 75 kDa, the expected size.

15

ATTORNEY DOCKET NO. 14014.0225

TABLE 6. Sequences of oligonucleotide primers used for PCR amplification

Primers	Sequences	RE sites
	5' 3'	
P1 (UCHT1 VL5)	GACATCCAGATGACCCAGAC	
P2 (UCHT1 VL3)	CCTCCCGAGCCACCGCTCCGCTGCCCTCCGCTCCTTTATCTCCAGCTG (T) GTC (G) CC	
P3 (UCHT1 VH5)	GCAGCGGAGGCGGTGGCTCGGGAGGGGAGGCTCGGAGGTGCAGCTTCAGCAGTCT	Hind III
P4 (UCHT1 VH3)	GCAAGCTTGAAGACTGTGAGAGTGGTGCCTTG	Hind III
P5 (HuIgM-CH2)	GTCCTCTTCAAAGCTTATTGCC (T) GAGCTGCCTCCCCAA	Xba I
P6 (HuIgM-CH4)	GCATCTAGATCAGTAGCAGGTGCCAGCTGTGT	Sal I
SP1		
(Signal SEQ 1)	CGGTCGACACCATGGAGACAGACACACTCCTGTTATGGGTACTGCTGCTGGGTCCA	
SP2	GTAAGTCTGCTCTGGGTCCAGGTCCACTGGGACATCCAGATGACCCAG	
(Signal SEQ 2)		

Expression in COS-7 and SP2/0 cells.

The gene fragment encoding scUCHT1 was then cloned into an expression vector pLNCX [36]. The scUCHT1 gene construct was introduced into COS-7 cells with a calcium-phosphate method [32], and introduced into SP2/0 myeloma cells by electroporation [33]. Cells transfected were selected with 500 μ g/ml G418 (GIBCO/BRL, Gaithersburg, MD, USA) in DMEM medium. The drug resistant transfectants were screened for scUCHT1 secretion by an anti-human IgM ELISA technique. Transfectants secreting scUCHT1 were cloned by limiting dilution.

Two stable clones, COS-4C10 and SP2/0-7C8, which could produce about 0.5 mg/ml scUCHT1 in culture medium, were selected for further evaluation. The culture supernatant of COS-4C10 and SP2/0-7C8 cells was analyzed by immunoblotting using anti-human IgM antibody (Fig. 5). Human IgM antibody was included as a control in the analysis. Under reducing conditions, scUCHT1 produced by COS-7 and SP2/0 cells had a similar electrophoretic mobility to that of the control human IgM heavy chain (75 kDa). Under non-reducing conditions, scUCHT1 from COS-7 cells appeared as a single band of approximately 150 kDa, which was thought to be a homodimer of the single chain antibody. SP2/0 cells mainly produced a protein of similar size with some higher molecular weight products.

In constructing scUCHT1, the domain orientation of sFv, V_H - V_L , which Shu et al. used to V_L - V_H orientation, was changed so that the heavy chain constant domains were linked to the V_H domain. In mammalian cells, secretion of immunoglobulin molecules is mediated by light chain, and free light chain is readily secreted [38]. However, free

heavy chain is generally not secreted [39]. In a bacterial expression system, the yield of secreted sFv with a V_L - V_H domain orientation was about 20-fold more than that obtained with a V_H - V_L domain orientation [40]. It was
5 reasoned that V_L at the NH_2 -terminal position and V_H linked to heavy chain constant region in scUCHT1 construct might enhance the secretion of this immunoglobulin-like molecule in mammalian cells. In fact scUCHT1 was efficiently produced by both COS-7 and SP2/0 cells. Hollow fiber
10 culture should increase its production. Moreover, scUCHT1, the IgM-like molecule, has a secretory tailpiece with a penultimate cysteine (Cys 575) which is involved in polymerization and also provides retention and degradation of IgM monomers [41-43]. Replacing the Cys 575 with
15 serine might also greatly improve the yield.

scUCHT1 secreted from COS-7 cells was shown to be a divalent form by immunoblotting, suggesting a disulfide bond linkage of two monovalent molecules. The disulfide
20 bond is likely situated between the CH2 and CH3 regions, where the Cys 337-Cys 337 disulfide bond is thought to exist. Cys 337 is believed to be sufficient for assembly of IgM monomers, and was neither sufficient nor necessary for formation of polymers. However, Cys 575 was necessary
25 for assembly of IgM polymers, and Cys 414 was not required for formation of IgM monomers or polymers [44]. This divalent form of the single chain antibody should increase its binding affinity. While scUCHT1 produced from SP2/0 cells was mainly in the divalent form, a small fraction of
30 the antibody had a higher molecular weight, nearly comparable to that of the human IgM pentamer, the natural form of secreted human IgM.

Western blotting analysis of scUCHT1.

scUCHT1 was precipitated from the culture supernatant using goat anti-human IgM-Agarose (Sigma, St. Louis, MO, USA), and separated on 4-20% SDS-PAGE gradient gel under
5 reducing and non-reducing conditions. The separated proteins were transferred to ProBlott™ membrane (Applied Biosystems, Foster City, CA, USA) by electroblotting at 50 volts for 1 hour. The membrane was blocked and incubated with alkaline phosphatase labeled goat anti-human IgM
10 antibody (PIERCE, Rockford, IL, USA) following the manufacturer's instruction. Color development was carried out with substrate NBT/BCIP (PIERCE).

Purification of scUCHT1.

15 Culture supernatant was mixed with anti-human IgM-Agarose, and incubated at 4°C with shaking overnight, and then the mixture was transferred to a column. The column was washed with washing buffer (0.01 M Na-phosphate, pH 7.2, 0.5 M NaCl) until the OD280 of
20 flow-through was <0.01. scUCHT1 was eluted with elution buffer (0.1 M glycine, pH 2.4, and 0.15 M NaCl). The fractions were neutralized with 1 M Na-phosphate (pH 8.0) immediately, and then concentrated and dialyzed against PBS.

25

Competitive binding assay.

The parental antibody UCHT1 was iodinated using Bolton-Hunter Reagent (NEN, Wilmington, DE, USA) as described previously [34]. The ¹²⁵I-labeled UCHT1 was used
30 as tracer and diluted with DMEM medium to 0.3-0.6 nM. UCHT1 and the purified scUCHT1 from COS-7 and SP2/0 transfectant cells were used as competitors. Human CD3 expressing Jurkat cells were suspended in DMEM medium (2 x

10⁷/ml). 50 μ l of such cell suspension (1×10^6) was incubated with 50 μ l diluted tracer and 50 ml diluted competitors on ice for 2 hours. Afterwards, cells were pelleted, and counted in a gamma counter. Results were
5 expressed as a percentage of the ¹²⁵I-UCHT1 bound to cells in the absence of competitors (Fig. 6).

scUCHT1 from both COS-7 and SP2/0 cells could specifically inhibit the binding of ¹²⁵I-UCHT1 to Jurkat
10 cells in a dose dependent way. As the concentration of the competitors (UCHT1, scUCHT1 from COS-7 and SP2/0 cells) increased from 1 to 100 nM, the tracer (¹²⁵I iodinated UCHT1) bound to Jurkat cells decreased from 80% to nearly 0%. No significant difference was
15 observed among the affinity curves of UCHT1 and scUCHT1 from COS-7 and SP2/0 cells. This indicates that the engineered antibody scUCHT1 has nearly the same affinity as UCHT1. Moreover, scUCHT1 contains human IgM constant region, and is expected be less immunogenic than UCHT1.
20 The degree of its immunogenicity might vary due to the murine variable region of scUCHT1. Humanized variable regions by CDR-grafting or human variable regions can be used to further reduce its immunogenicity [31].

25 **T-cell proliferation assay.**

T-cell proliferation in response to UCHT1 and scUCHT1 was tested on human PBMCs from a healthy donor (Fig. 7). Human peripheral blood mononuclear cells (PBMCs) were isolated from blood of a healthy adult by density
30 centrifuge over Ficoll-Hypaque gradient [34]. The PBMCs were resuspended in RPMI 1640 supplemented with 10% FCS and aliquoted to 96-well U-bottom plates at 5×10^4 cells/well. Increasing amounts of anti-CD3 antibodies

(UCHT1, scUCHT1) were added. After 72 hours of culture at 37°C in a humidified atmosphere containing 5% CO₂, 1 µCi [³H]thymidine (NEN) was added to each well. 16 hours later, cells were harvested and [³H]thymidine incorporation was counted in a liquid scintillation counter.

The parental antibody UCHT1 started to induce proliferation at 0.1 ng/ml, and peaked at 100 ng/ml. A small drop in CPM was observed as the concentration increased to 1,000 ng/ml. However, [³H]thymidine incorporation in PBMCs incubated with scUCHT1 was only slightly increased in the range of 0.1 - 10 ng/ml, and when the concentration was higher than 10 ng/ml, the incorporated counts decreased and were close to 0 counts at 1,000 ng/ml.

Measurement of TNF-α and IFN-γ.

TNF-α and IFN-γ productions of human PBMCs induced by UCHT1 and scUCHT1 were measured with ELISA. 4 x 10⁵ PBMCs were cultured with serial dilutions of anti-CD3 antibodies (UCHT1, scUCHT1) in 96-well flat-bottom plates in RPMI 1640 supplemented with 10% FCS. Supernatant was collected at 36 hours for TNF-α and 72 hours for IFN-γ after the start of the culture [35]. TNF-α and IFN-γ were measured with ELISA kits (Endogen Inc. Cambridge, MA, USA) following the manufacturer's instruction.

The native antibody UCHT1 induced production of both TNF-α and IFN-γ in a dose dependent way (Fig. 8a and 8b). Higher concentration of UCHT1 induced higher production of TNF-α and IFN-γ. On the contrary, scUCHT1 did not induce secretion of TNF-α at any concentration (Fig. 8a), and inhibited IFN-γ production when its concentration was

higher than 0.1 ng/ml (Fig. 8b). At the time of supernatant harvesting, the PBMCs cultured with UCHT1 and scUCHT1 were also checked with trypan blue exclusion test. Cells were shown to be alive in both situations. In TNF- α and IFN- γ ELISA assays, an unrelated human IgM was included and it did not affect the TNF- α and IFN- γ production.

Anti-CD3 mAbs can induce T cell activation and proliferation both in *in vitro* and *in vivo* situations [45]. Crossing-linking of anti-CD3 antibody between T cells and FcR expressing cells is an essential step in this process [46]. T cell activation therefore reflects an efficient interaction of the mAb with a human FcR. Previous data of *in vitro* study indicated that T cell activation resulted in increased production of TNF- α , IFN- γ , and IL-2 [24]. Human IgG Fc receptors (Fc γ R I, Fc γ R II, Fc γ R III) are distributed on human monocytes, T, B lymphocytes, and NK cells [47]. Fc γ R I and Fc γ R II can recognize both mouse and human IgG. In accordance with the above observation, UCHT1 was potent in induction of T cell proliferation and TNF- α and IFN- γ release. Human IgM Fc receptor (Fc μ R) was reported to be present mainly on a small fraction of B lymphocytes, NK cells, and possibly a helper subset of T lymphocytes [47, 48]. Pentamer form of IgM and an intact CH₃ domain are required for optimal binding to Fc μ R. Monomeric or dimeric subunits of IgM are less efficient in binding to Fc μ R [49, 50]. Cross-linking of IgM to Fc μ R on T cells inhibited the mitogen-induced T cell proliferation, and Fc μ R may function as a negative signal transducing molecule [51, 52].

Therefore, it can specifically bind to human CD3 molecule and Fc μ R. It is conceivable that scUCHT1 can cross-link human B and T cells, and possibly T and T cells. In an *in vitro* assay, scUCHT1 from both COS-7 and
5 SP2/0 cells had little effect in the T cell proliferation assay at low concentrations (below 10 ng/ml), and became inhibitory as the concentration increased. In accordance with these results, scUCHT1 did not induce TNF- α production and even inhibited the basal yield of IFN- γ .

10

The present chimeric anti-CD3 single chain antibody scUCHT1 possesses high human CD3 binding specificity and affinity, and does not induce T cell proliferation and cytokine release. Moreover, it has a human IgM Fc
15 fragment, which should decrease the possibility of inducing human anti-mouse antibody response. Thus, scUCHT1 can be used for clinical immunosuppressive treatment.

20

EXAMPLE 11

Cloning the full-length of DT gene for the construction of DTM2.

25 Corynebacteriophage beta (*C. diphtheriae*) tox 228 gene sequence was from genebank. (Science 221, 885-858, 1983). The sequence is 2220 bp. There are 300 bp of 5' untranslated region (1 to 300) including the promoter sequence around (-180 to -10), 1682 of coding region (301-
30 1983) including signal peptide (301 to 376), A chain (377 to 955) and B chain (956 to 1983), and 3' untranslated region (1984 to 2220).

ATTORNEY DOCKET NO. 14014.0225

The full-length DT was amplified in two fragments. The pelB leader sequence (ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTGCGCT GCC CAA CCA GCG ATG GCC 3') SEQ ID NO:1) was added to the 5' end of the DT
5 coding sequence to all the constructs during polymerase chain reaction by primer EcosignalDT-1 and EcosignalDT-2. The upstream fragment of 311 bp (from position 301 to 546 bp) was amplified by oligo EcosignalDT-2 and p546R with CRM9 DNA as a template and the downstream fragment of 1471
10 bp was amplified by p514S and p1983R with the DTM1 DNA as template. Then, the combined PCR product of full-length DT was amplified with primer EcosignalDT-1 and p1983R. As a result, the amplified DT coding sequence (position 376 to 1983bp) acquired the pelB leader sequence added to the 5'
15 end and contains the two mutant sites [(508 Ser to Phe) and (525 Ser to Phe)] as DTM1 does.

Primers:

EcosignalDT-1 5' ATG AAA TAC CTATTG CCT ACG GCA GCC
20 GCT GGA TTG TTA TTA CTC GCT GCC CAA 3' (SEQ ID NO:2)
EcosignalDT-2 5' GGA TTG TTA TTA CTC GCT GCC CAA CAA
GCG ATG GCCGGC GCT GAT GATGTT GTT GAT TC 3' (SEQ ID NO:3)
p546R: 5' CGGTACTATAAAACTCTTTCCAATCATCGTC 3' (SEQ ID NO:4)
p514S: 5' GACGATGATTGGAAAGAGTTTTATAGTACCG 3' (SEQ ID NO:5)
25 p1983R: 5'AGATCTGTCGA/CTCATCAGCTTTTGATTTCAAAAATAGCG 3'
(SEQ ID NO:6).

A mutant residue was introduced at position 52. The glycine (GGG) at position 52 wild type DT was substituted
30 by glutamic acid (GAG). The two primers p546R and p514S carried the mutant codon (GGG to GAG). The PCR products of these two primers contained the substituted codon (GAG) instead of codon GGG. The jointed double stranded DNA of

the two fragments (1683bp) were cloned into pET 17b by restriction site NdeI and BamHI.

5 The data show that anti-human blocking antibodies are specifically directed at the toxin C-terminus. Although a specific sequence derived from the UCHT1 VLVH regions is described, anyone skilled in the art could make sequence variations in VLVH domains which can be designed to increase the affinity of the sc-anti-CD3-antibody
10 conferring a more favorable therapeutic ratio to fusion immunotoxins using this derivative. Such modifications are within the scope of the present teaching. The disadvantage of the monovalent antibody VLVH construct, is that it has a lower affinity for T cells compared to the
15 chemically coupled conjugate which utilizes a divalent antibody.

These are believed to be the first instances of a sc anti-CD3 antibodies. IgM was chosen since very few B
20 cells or macrophages contain IgM Fc receptors. (Binding of immunotoxin to cells other than T cells reduces the specificity of the anti-T cell immunotoxin and this situation is purposefully avoided). However, using a bacterial expression system no carbohydrate is attached to
25 the antibody which also eliminates Fc receptor binding. Thus, substituting other human IgG constant domains would be a routine modification and should be claimed.

A variety of divalent fusion protein immunotoxins are
30 provided. These have been expressed in *E. coli*, and Western blots of reduced and non-reduced SDS gels confirm that most of the immunotoxin is secreted as the dimeric (divalent) species (Fig. 9). The position of the toxin

has been varied in an attempt to minimize stearic hindrance of the divalent antibody site, yet provide the best interactions with the CD3 receptor to facilitate toxin translocation across the membrane. Fig. 10 diagrams PCR amplification. Figs. 11 and 12 show two different clones expressing divalent immunotoxin fusion proteins cartooned in Figs. 13 and 14, respectively. Another variation is shown in Fig. 15. The clone producing this consists of a clone constructed by using the single chain antibody followed by a stop codon and the single chain immunotoxin, all under one promotor (Better et al. *Proc. Natl. Acad. Sci.* 90:457-461, January 1993). After secretion and oxidation of the interchain disulfide, 3 species are present: sc divalent antibody, divalent fusion immunotoxin, and a divalent sc antibody containing only one toxin. This species is isolated by size separation and is the species cartooned in Fig. 15. The advantage of this species is that stearic hindrance to the divalent antibody domains is limited by the presence of only one toxin domain. Other variations are routine to construct given the methods described herein and in the art. Those diagramed are considered to be the most likely to exhibit divalent character. Numerous orientations of toxin relative to antibody domains can be made and many are expected to be effective.

In addition, the length of the toxin C-terminus has been varied to provide optimization between two competing functions. The numbers after DT refer to the number of amino acid residues counting the amino terminus of the toxin A chain as 1. The full length toxin is called DTM1 and was provided by Dr. Richard Youle NINDS, NIH (Nicholls et al. *J. Biol. Chem.* 268(7):5302-5308, 1993). It has

point mutations S to F at positions 508 and 525. This full length toxin mutant has the essential mutation of CRM9, S to F at 525 which reduces binding to the DT receptor by 3-4 logs without abolishing the translocation function. The other mutation S to F at 508 has been added because of previous restrictions on cloning mutant DT that can revert to wild type toxin with a minimum lethal dose of 0.1 microgram/kg by means of a single base pair reversion. Other mutations can be routinely made in the C terminus to perform this function (Shen et al. *J. Biol. Chem.* 269(46):29077-29084, 1994). They are: F530A; K526A; N524A; V523A; K516A Y514A. A clone having a single point mutation in DT reducing toxicity by 10-100 fold can be made providing that the clone contains an antibody fragment fusion protein, because chemical conjugation of antibody to DT has been shown to reduce systemic wild type toxin toxicity by 100 fold (Neville et al. *J. Biol. Chem.* 264(25):14653-14661, 1989). Therefore, the present invention provides a full length mutant DT sequence with the 525 S to F mutation alone as well as those listed above. These same mutations are also contemplated for the B chain mutant site in DTM2 and can be made similarly. Previous data with chemical conjugation has shown that the longer the C-terminus the better the translocation function (Colombatti et al. *J. Biol. Chem.* 261(7):3030-3035, 1986). However, the shorter the C-terminus the less effect of circulating anti-toxin blocking antibodies. Since patients have different levels of blocking antibodies which can be measured (see toxicity assay in), the optimal immunotoxin can be selected for individual patients. scUCHT1 fusion proteins with DTM1 and DT483 (see Fig. 16), DT390 (Fig. 17) and DT370 (Fig. 18) have been cloned and expressed in *E. coli*. Each of these

ATTORNEY DOCKET NO. 14014.0225

variations as well as the divalent scUCHT1 fusion proteins using each of these toxin domains are provided.

5 The present invention provides an improvement on
CRM197 (a non-toxic toxin mutant described in U.S. Serial
No. 08/034,509, filed September 19, 1994) referred to
herein as DTM2. DTM2 has the same mutation as CRM197 plus
two mutations in the C-terminus which block binding (see
sheet and Fig. 9). This is expected to reduce the
10 likelihood of immune complex disease which could result
when CRM197 becomes bound to cells and then is further
bound by circulating antitoxin. Kidneys are particularly
susceptible. DTM2 can not bind to cells thereby lessening
the possibility of tissue damage. In addition DTM2 is
15 made for high level production by including the pelB
secretory signal for production in *E. coli* or a iron
independent mutated promoter DT sequence cloned from CRM9
DNA for production in *C. diphtheriae*. The essential
feature of DTM2 is the S to F mutation at 525 and the G to
20 E mutation at 52, and a construct containing these two
mutations is provided.

25 All of the constructs reported here can be expressed
in *E. coli* using pelB signal sequences or other
appropriate signal sequences. Expression can also be
carried out in *C. diphtheriae* using appropriate shuttle
vectors (Serwold-Davis et al. *FEMS Microbiol. Letters*
66:119-14, 1990) or in protease deficient strains of *B.*
subtilis and using appropriate shuttle vectors (Wu et al.
30 *Bio. Technol.* 11:71, January 1993).

EXAMPLE 12

Thymic Injection and Tolerance Induction in Primates

5 Without thymic treatment, rhesus monkey renal
allografts reject at a mean of 7 days. Renal allografts
in rhesus monkeys (age 2-5 years; 2-3 kg body weight) were
performed. The experimental protocol consisted of first
10 selecting MHC class I disparate rhesus monkey donors and
recipients. Donor lymphocytes were injected into the
recipient thymus gland 7 days prior to renal allografting
from the same donor. Recipients received the immunotoxin
of the present invention by intravenous injection. Renal
allografts were performed and recipients underwent native
15 nephrectomy.

Immunotoxin

Techniques for preparing anti-CD3-CRM9 (where the
antibody is directed at the human T-cell receptor complex
20 "CD3") have previously been described. See U.S. patent
5,167,956 and D. Neville et al., 89 P.N.A.S. USA 2585-2589
(1992). A hybridoma secreting UCHT1 was kindly provided
by Dr. Peter Beverly, Imperial Cancer Research Fund, and
was grown in ascites fluid and purified over immobilized
25 Protein A. This is an IgG1.

FN18, also an IgG1, is the rhesus analog of UCHT1 and
shares with it the property of being a T-cell mitogen in
the presence of mixed mononuclear cells. FN18 was
30 produced in hollow fiber and purified over Protein A. The
strain of *C. diphtheriae* used for production of CRM9, C7
(β h tox-201 tox-9 h') was obtained from R. Holmes,
Uniformed Services University of Health Sciences,

Bethesda, MD. See also V. Hu et al., 902 Biochimica et Biophysica Acta 24-30 (1987).

Antibody-CRM9 was recovered from the supernatant of
5 30 liter fermentation runs under careful control of iron
concentration. See S.L. Welkos et al., 37 J. Virol. 936-
945 (1981). CRM9 was purified by membrane concentration,
ammonium sulfate precipitation and chromatography over
DEAE. See S. Carroll et al., 165 Methods In Enzymology 68
10 (1988).

Large scale purification of immunotoxin was
accomplished by HPLC size exclusion chromatography on
MODcol (1266 Andes Blvd., St. Louis, Missouri 63132)
15 "2x10" column packed with Zorbax (DuPont Company) GF-250
5 μ m, 150 Å. Fractions containing 1:1 toxin:antibody mol
ratios were isolated for these studies.

Immunotoxins were synthesized as previously described
20 by thiolating both the monoclonal antibody moiety and the
toxin moiety and then crosslinking with
bismaleimido-hexane. See D. Neville et al., 264 J. Biol.
Chem. 14653-14661 (1989). CRM9 was nicked and the monomer
(Carroll et al.) was isolated by the MODcol column
25 described above prior to thiolation.

While CRM9 is a presently preferred mutant diphtheria
toxin protein, other preferred embodiments include
diphtheria mutants with a mutation in the DT binding
30 region, such as DT390, should also be suitable (as the
concept behind the immunotoxin is to replace the normal
binding function with the antibody provided T-cell binding
function, with minimal conformational change).

T-Cell Ablation

Monoclonal antibody FN18 (specific for rhesus monkey T lymphocytes) coupled to the immunotoxin CRM9 was used to deplete peripheral blood T-cells to levels below 200 cells /M13 in adult rhesus monkeys (measured six days after the injection). Some modest B cell depletion occurred. Following depletion, complete T-cell recovery takes about three to four weeks in a juvenile rhesus monkey model using this agent. Surprisingly, notwithstanding this fast recovery, donor T-cells injected into the thymus still were not impaired in their ability to produce tolerance.

Four monkeys received .2 mg/kg of immunotoxin, in three divided doses (24 hours apart from each other). Another monkey received .133 mg/kg immunotoxin in two divided doses (24 hours apart from each other), and the other monkey received .1 mg/kg in two divided doses (24 hours apart from each other). Two days after the last dose of immunotoxin, all monkeys except the last had at least 80% (actually greater than 99%) depletion of T cells both in the peripheral blood and in the lymph nodes. The lowest dose used in the last monkey reduced, but did not substantially eliminate either peripheral blood or lymph node lymphocytes.

25

Lymphocytes

Lymphocytes to be donated are preferably pooled from axillary and cervical lymph nodes of a single donor. The nodes are harvested, strained through a mesh to separate the lymphocytes, diluted with saline, and then injected. Alternatively, a representative "cocktail" of lymphocytes from several primates other than the donor, at least one of which turns out to be the same haplotype as the likely

[illegible][illegible][illegible]

TABLE 7 - Renal Allograft Survival by Treatment Group*

<u>Monkey</u>	<u>Intrathymic injection</u>	<u>FN18-CMR9</u>	<u>Survival (days)</u>
T4T	none	none	5
X9X	none	none	7
1FE	none	none	7
H7C	10.6 x 10 ⁸ donor lymphocytes	none	1
W7C	9.1 x 10 ⁸ donor lymphocytes	none	1
93023	7.0 x 10 ⁸ donor lymphocytes	0.2 mg/kg	>517
92108**	1.9 x 10 ⁸ donor lymphocytes	0.2 mg/kg	181
POJ	7.5 x 10 ⁸ donor lymphocytes	0.2 mg/kg	> 340
POF	normal saline	0.2 mg/kg	> 368
PIP	normal saline	0.2 mg/kg	> 250
W7D	none	0.2 mg/kg	51
POG	none	0.2 mg/kg	84
PIN	none	0.2 mg/kg	> 165
X3J	none	0.2 mg/kg	> 117

* FN18-CRM9 was given on day -7, -6, -5 at a total dose of 0.2 mg/kg, i.v. Lymphocytes and saline were injected intrathymically on day -7. ** (acute rejection 40 days after skin graft)

ATTORNEY DOCKET NO. 14014.0225

Two monkeys died of pneumonia, one at 39 days and the other at 13 days. A third monkey died at 8 days of complications stemming from a urine leak. At autopsy, none of these three monkeys had any evidence of renal transplant rejection, either grossly or histologically.

Monkey #93023, which received the intrathymic injection and immunotoxin seven days prior to renal transplantation, had normal renal function more than 180 days post-transplant. A renal biopsy of his transplanted kidney at 100 days showed no evidence of rejection.

Surgical Procedures

Preferred surgical procedures include partial median sternotomy for exposure of the thymus and injection of donor lymphocytes into the thymus gland; inguinal and axillary lymphadenectomy to procure donor lymphocytes; laparotomy for procurement of the left kidney from kidney donors; and a second laparotomy for renal transplantation and native right nephrectomy. All of these procedures are performed under general anesthesia as outlined below. Serial blood draws are performed under ketamine and xylazine anesthesia as outlined below.

Thymic injection is performed through a midline chest incision beginning at the sternal notch extending down to the midportion of the sternum. The sternum is divided and retracted to expose the underlying thymus gland. The thymus gland is injected with donor lymphocytes and the sternum reapproximated and the soft tissue closed.

Donor nephrectomy is performed under general anesthesia through an upper midline incision in the

[illegible]

25 Lymphadenectomy is performed through an approximately 2 cm groin incision for inguinal lymphadenectomy and a similar length incision for axillary lymphadenectomy. The lymph nodes are excised and bleeding points cauterized. The skin is then closed with running 4-0 nylon suture.

30 It should be appreciated that kidney transplants are merely an example application. The invention should be suitable for use with a wide variety of organs (e.g.

liver, heart, lung, pancreas, pancreatic islets and intestine).

In sum, surprisingly immunotoxins known to severely
5 deplete T-lymphocytes will selectively deplete the host
lymphocytes, without interfering with the donor T
lymphocytes ability to cause tolerance. Further, the
extreme level of depletion caused by this immunotoxin
facilitates induction of tolerance.

10

EXAMPLE 13

**Anti-CD3-CRM9 Immunotoxin Promotes Tolerance in
Primate Renal Allografts**

15

The ability of thymic injection and transient T
lymphocyte depletion to permit development of donor-
specific tolerance to rhesus monkey renal allografts was
investigated. For T cell ablation, the immunotoxin
20 FN18-CRM9, was used that depletes T cells from both the
lymph node and blood compartments (see Example 5 and
Neville et al. J Immunother 1996 (In press)). FN18-CRM9
is composed of an anti-rhesus monkey CD3 monoclonal
antibody (mAb), FN18 (Neville et al., 1996), and a binding
25 site mutant of diphtheria toxin, CRM9 (Neville et al. Proc
Natl Acad Sci USA; 89: 2585-2589 (1992)). Compared to
other anti-T cell agents used in clinical and experimental
transplantation, FN18-CRM9 produces more effective killing
of T cells, and this was the rationale for its choice as
30 an agent to promote transplantation tolerance.
Anti-CD3-CRM9 alone successfully delayed graft rejection.
T cell depletion with anti-CD3-CRM9 combined with thymic
injection prolonged graft survival to > 150 days in five

of five recipients and induced donor-specific tolerance in four of five recipients. Donor skin grafts were accepted long-term, whereas third party skin grafts were promptly rejected. These results are unique in their reliable
5 induction of donor-specific tolerance as confirmed by skin grafting in a non-human primate model. This approach to tolerance reasonably correlates to induction of tolerance in humans.

10 **MHC Typing and Donor-Recipient Selection.**

Donor-recipient pairs were selected based on maximizing MHC disparity. This was based on pre-transplant cytotoxic T lymphocyte (CTL) and mixed lymphocyte reaction (MLR) analysis (Derry H, Miller RG.
15 Fathman CG, Fitch FW, eds. New York: Academic Press, 510 (1982) and Thomas et al. Transplantation, 57:101-115 (1994)), analysis of MHC class I differences by one-dimensional isoelectric focusing (1-D IEF) (Watkins et al. Eur J Immunol; 18:1425-1432 (1988)), and evaluation of
20 MHC class II by PCR-based analysis.

Flow Cytometry.

Two x 10⁵ lymphocytes obtained from peripheral blood or inguinal, axillary, or mesenteric lymph nodes were
25 stained with FITC-labeled FN18 or isotype control antibody. Cells were subjected to flow cytometry on a Benton Dickenson FACSCAN.

Animals and Surgical Procedures.

30 Outbred male juvenile rhesus monkeys (ages 1 to 3 years), virus free, were used as donors and recipients. Surgical procedures were performed under general anesthesia, using ketamine, 7 mg/kg, i.m., and xylazine, 6

mg/kg, i.m. induction, and inhalation with 1% halothane to maintain general anesthesia. Post-operatively, monkeys received butorphanol, 0.25 mg/kg, i.v., and aspirin, 181 mg, p.o., for pain control. Thymic injection was

5 performed via a limited median sternotomy to expose the thymus gland. Seven days before renal transplantation, each lobe of the thymus was injected with donor lymphocytes suspended in 0.75 to 1.0 ml normal saline using a 27 gauge needle. Donor lymphocytes were procured

10 from the inguinal, axillary, and mesenteric lymph nodes of the donor, counted and resuspended in normal saline for injection. Heterotopic renal transplants were performed using the donor left kidney. Following transplantation, the recipient underwent native nephrectomy. Graft

15 function was monitored by measuring serum creatinine. Rejection was diagnosed by rise in serum creatinine to > 0.07 mol/L, no evidence of technical problems, such as urine leak or obstruction at autopsy, and histologic confirmation. Monkeys were killed with a lethal dose of

20 sodium pentobarbital if they rejected their kidney, and were autopsied. To test for tolerance, full thickness skin grafts were placed using ventral abdominal skin from donors placed onto the dorsal upper back of recipients. Grafts were evaluated daily by inspection.

25

Immunosuppression.

FN18-CRM9 was chemically conjugated and purified as

30 described (Neville et al. 1996). It was administered intravenously at a dose of 0.2 mg/kg in 3 divided daily doses starting 7 days prior to renal transplantation. No additional immunosuppressive drugs were given to any of

the monkeys, and monkeys were not isolated from environmental pathogens.

5 The effect of FN18-CRM9 on rhesus peripheral blood
lymphocytes and lymph node lymphocytes is summarized in
Figures 19a and 19b. In addition to causing transient T
cell depletion from the peripheral blood, FN18-CRM9
depleted lymph node lymphocytes almost completely at the
dose given and when measured 0-4 days after the third dose
10 of drug. Absolute leukocyte counts did not change
significantly with treatment. Recovery times were
variable, but in general peripheral blood T lymphocytes
returned toward baseline levels 2 to 4 weeks following
treatment. Recovery rates varied between individual
15 monkeys.

Untreated monkeys acutely rejected their allografts
(n=3) within one week (Table 7). Monkeys receiving
lymphocytes intrathymically but no anti-CD3-CRM9 developed
20 hyperacute rejection within 24 hours (Table 7) with the
typical histologic features of hemorrhage, infarction, and
a dense neutrophil and lymphocyte infiltrate. Three of
three recipients treated with donor lymphocytes
intrathymically and anti-CD3-CRM9 had long-term graft
25 survival (Table 7). One monkey (92108) rejected its
kidney 40 days after a donor and third party skin graft
were placed to test for donor-specific tolerance. This
monkey rejected its third party skin graft at 10 days and
a lymphocyte infiltrate in the donor skin graft developed
30 with rejection of the renal allograft 40 days later. The
other two recipients of donor lymphocytes and
anti-CD3-CRM9 were successfully skin grafted from the
donor with survival of these skin grafts for more than 100

days, but rejection of third party skin grafts at 10 days. All biopsies of their renal allografts showed an interstitial infiltrate but no evidence of glomerular or tubular infiltrates or injury. Two monkeys receiving
5 normal saline injections in the thymus in combination with anti-CD3-CRM9 became tolerant of their renal allografts. Both of these monkeys rejected a third party skin graft at 10 days and have had long-term survival of donor skin grafts. The results of all skin grafts are summarized in
10 Table 8. Renal biopsies of long-surviving tolerant recipients demonstrated focal interstitial mononuclear infiltrates without invasion or damage of tubules or glomeruli. Monkeys treated with anti-CD3-CRM9 alone developed late rejection in two cases at day 54 and day 88
15 and the histology of their kidneys at autopsy demonstrated a dense lymphocytic infiltrate. In two other cases, long-term unresponsiveness was observed (Table 7) to > 127 days and > 79 days. The thymuses of the two monkeys which rejected their grafts were markedly decreased in size at
20 autopsy compared to age-matched controls prior to treatment, but a small thymic remnant was identified.

The data demonstrate that anti-CD3-CRM9 is a potent, new immunosuppressive agent which is capable of inducing
25 tolerance in outbred MHC class I and class II disparate rhesus monkeys. This attribute distinguishes it from other currently known immunosuppressive agents, such as antithymocyte globulin, cyclosporine, or monoclonal antibodies which have more limited efficacy or safety in
30 tolerance induction in large mammals or which require more cumbersome strategies (Powelson et al., Transplantation 57: 788-793 (1994) and Kawai et al., Transplantation 59: 256-262 (1995)). The degree of T cell depletion produced

by 3 doses of the drug is more complete than that achieved by a longer course of anti-lymphocyte globulin, which generally depletes to a much lesser degree (Abouna et al., Transplantation 59: 1564-1568 (1995) and Bourdage JS, Hamlin DM, Transplantation 59:1194-1200 (1995)). Unlike OKT3, an activating antibody which does not necessarily kill T lymphocytes, anti-CD3-CRM9 is a lytic therapy with a more profound effect on T cells than OKT3 and better potential for tolerance induction. Its efficacy may be in part related to its ability to deplete T cells in the lymph node compartment, as well as in peripheral blood, since the majority of potentially alloreactive T cells reside in the lymph node compartments. The T cell depletion produced by anti-CD3-CRM9 is more complete than that achieved by any other known pharmacologic means, including total lymphoid irradiation, and it avoids the toxic side effects of radiation. Following treatment with the anti-CD3-CRM9, the thymus decreases markedly in size, although thymic cortex and medullary structures are still apparent. Anti-CD3-CRM9 appears to be safe and well tolerated in rhesus monkeys. No significant adverse drug effects were encountered. About half of the monkeys were treated with intravenous fluids for 3 to 5 days following administration to prevent dehydration. No infections were encountered in these experiments and only routine perioperative antibiotic prophylaxis was used at the time of renal transplantation and thymic injection. Cytokine release syndrome was not seen and monkeys did not develop febrile illness following drug administration.

30

The induction of tolerance in monkeys receiving thymic injection of either donor lymphocytes or normal saline in conjunction with anti-CD3-CRM9 suggests that thymic

injection may provide an adjunct to tolerance induction using T cell depletion with anti-CD3- CRM9. Presumably, CD3+ lymphocytes present in the donor lymphocyte inoculum are also killed by the drug administered to the

5 recipients. This would leave donor B cells to express donor MHC class I and class II in the recipient thymus. Rodent studies would suggest that it is the presence of one or both of these antigens that is crucial to promoting thymic tolerance (Goss JA, Nakafusa Y, Flye MW, Ann Surg

10 217: 492-499 (1993); Knechtle et al., Transplantation 57: 990-996 (1994) and Oluwole et al., Transplantation 56: 1523-1527 (1993)). Of even more interest is the observation that normal saline injected into the thymus in conjunction with anti-CD3-CRM9 produced tolerance in two

15 of two recipients. Surprisingly, the success of this approach suggests that immunotoxin rather than thymic injection is crucial. Alternately, non-specific disruption of thymic integrity may contribute

20 The observation that two of four recipients treated with anti-CD3-CRM9 alone became tolerant suggests that transient depletion of T cells by the drug is crucial in promoting tolerance. In rodents, transplant tolerance can be achieved by concomitant administration of donor antigen

25 and anti-T-cell agents (Qin S et al., J Exp Med 169: 779-794 (1989); Mayumi H, Good R.A., J Exp Med 1989; 169: 213-238 (1989); and Wood ML et al., Transplantation 46: 449-451 (1988)), but this report demonstrates donor-specific tolerance using T cell specific therapy

30 alone. The depletion of T cells from the lymph node compartment by anti-CD3-CRM9 may be crucial in promoting its efficacy as a tolerance inducing agent and differentiate it from anti-CD3 mAb alone which depletes

ATTORNEY DOCKET NO. 14014.0225

the peripheral blood CD3 cells, but has a weaker effect on the lymphoid tissues (Hirsch et al., J Immunol 140: 3766-3772 (1988)).

5 These experiments using an outbred, MHC incompatible non-human primate model provide a rationale for tolerance strategies in human organ transplantation. The results are unique in offering a simple, reliable, and safe approach to tolerance in a model immunologically analogous
10 to human solid organ transplantation. An anti-human CD3 immunotoxin (e.g., scUCHT1-DT390 and anti-CD3-CRM9) has been constructed and has T cell killing properties similar to FN18-CRM9 (see Neville 1992 and Neville 1996). The preliminary results reported here have broad implications
15 for tolerance in humans.

 In summary, immunotoxin treatment alone leads to marked prolongation of graft survival in 100% of the cases to date. Eliminating the thymic manipulation did not
20 alter the success rate. No other drug or treatment regimen comes close to achieving these results in primates.

Table 8 - Skin Graft Results

<u>Monkey</u>	<u>Interval after kidney transplant</u>	<u>3rd party skin survival (days)</u>	<u>Donor skin survival (days)</u>
93023	182	10	> 367
92108	140	1040	(and renal allograft rejection)
POF	147	10	> 221
POJ	188	10	> 152
PIP	176	10	> 74

EXAMPLE 14

Immunotoxin Alone Induces Tolerance

5 Depletion of mature T cells can facilitate stable acceptance of MHC mismatched allografts, especially when combined with donor bone marrow infusion. Although ATG and anti-T cell mAbs eliminate recirculating cells, residual T cells in lymphoid tissue have potential to
10 orchestrate immune recovery and rejection. Unlike pure antibodies, CD3-immunotoxin (CD3-IT) can destroy cells following direct binding and intracellular uptake without limitations of immune effector mechanisms. Thus, CD3-IT may have superior immunosuppressive activity. The action
15 of CD3-IT in rhesus monkey kidney transplant recipients was examined.

The present example of CD3-IT is a conjugate of IgG1 mAb anti-rhesus CD3 epsilon (FN18) and a mutant diphtheria
20 toxin CRM9 (FN18-CRM9). The B chain of CRM9 diphtheria toxin bears a mutation that markedly reduces binding to diphtheria toxin receptors, allowing specificity to be directed by anti-CD3.

25 CD3-IT was administered to 3-5 kg normal male rhesus monkey allograft recipients at a dose of 67 µg/kg on days-1 and 33 µg/kg on days +0 and +1 without additional immunosuppressive drugs. Recipient-donor combinations were selected to be incompatible by MLR and multiple DR
30 allele mismatches; and all were seronegative for CRM9-reactive antibody to diphtheria toxin. Three groups received CD3-IT: (1) alone (n=3), (2) in combination with day 0 infusion of donor bone marrow DR⁻CD3⁻ (n=3), (3) or

with donor bone marrow and 200 cGy lymphoid irradiation given on days -1 and 0 (n-3).

Kidney allograft survival was remarkably prolonged.

5 With CD3-IT alone, graft survival time was 57, 51, and 44 days. In combination with donor bone marrow infusion, graft survival was >400, 124, and 36 days. CD3-IT, lymphoid irradiation, and donor bone marrow resulted in

10 graft survival of >300, 143, and 45 days. Both the 36 or 45 day graft losses were from hydronephrosis without evidence of rejection. Peripheral blood T cell counts fell selectively by 2 logs, and time to 50% recovery was 20-60 days. The peripheral blood CD3+CD4/CD8 ratio increased 2-6 fold before adjusting to baseline by 3

15 weeks. B cell/T cell ratios in lymph nodes were elevated >40-fold on day 5-7, reflecting a 1-2 log reduction in circulating and fixed tissue T cell compartments. LN CD4/CD8 ratios were normal at 5-7 days, but CD45RA+CD4 and CD28-CD4 cell subsets increased >1 log while CD28+ CD8

20 cells decreased by >1 log, suggesting functional subset changes.

Anti-donor MLR responses became reduced uniformly, but specific unresponsiveness was seen only in the donor bone

25 marrow-treated group. Peripheral blood microchimerism was detectable by allele specific PCR after donor bone marrow-infusion. These studies show CD3-IT to be an unusually effective and specific immunosuppressive agent in non-human primate transplantation and provides clinical

30 tolerance induction strategies applicable to transplantation in humans.

EXAMPLE 15

**Immunotoxin Plus Short Term Immunosuppressant Drugs
Induces Tolerance in Monkeys in Models Simulating
Human Cadaveric Donors**

5 The efficacy of IT in prolonging allograft survival was evaluated in a model that stimulates transplantation of organs from cadaveric donors in humans. Rhesus monkey donor-recipient pairs were selected on the basis of MHC class I and II disparity. Monkeys were given anti-CD3-CRM9 immunotoxin 0.2 mg/kg iv in three divided daily doses starting on the day of the renal allograft (group 1). In group 2, recipients also received methylprednisolone 125 mg iv daily for 3 days and mycophenolate mofetil 250 mg po daily for 3 days starting on the day of the transplant. Rejection was monitored by serum creatinine levels and confirmed histologically.

Graft Survival (days)		
Group 1 (IT alone)	Group 2 (IT+MMF+methylprednisolone)	Group 3 (untreated)
79	>90	5
57	>75	7
51	>60	7
>124		
>102		

30 The short burst of intensive anti-T cell therapy given at the time of the transplant appears to be well tolerated and to reliably result in long-term allograft survival. The mRNA cytokine profile of graft infiltrating cells obtained from renal transplant biopsies in this protocol

ATTORNEY DOCKET NO. 14014.0225

suggests that IL-2 and γ -IF (TH₁ associated) are present in measurable levels and IL-4 and 10 (TH₂ associated) are detected at much lower levels. These results in a non-human primate model provide a strategy that can be applied to human organ transplant recipients who would benefit substantially from independence from maintenance immunosuppressive drugs.

A second group of rhesus monkeys undergoing mismatched renal transplantation received anti-CD3-CRM9 (IT) 18 hours pretransplant, 0.067 mg/kg and 0.033 mg/kg on days 0 and +1. Group 1 received only IT, n=6. Group 2, n=7, received in addition to IT deoxyspergualin (DSG) IV 2.5 mg/kg/day and solumedrol (SM), 7, 3.5 and 0.33 mg/kg IV during the IT administration. DSG was continued from 4 to up to 14 days. Plasma samples were tested by ELISA for cytokine release syndrome by measuring pre and post transplant plasma IL-12 and INF gamma levels.

Graft Survival (days)

Group 1 (IT alone)	Group 2 (IT + DSG + SM)
10-57 n=6 (rejections)	>155-200 n=4
	28-45 n=3 (rejections)
	2 deaths from
	non-rejection causes

IT, Group I, (or rhesus anti-CD3 an antibody alone) elevated both IL-12 and INF-8 gamma. DSG and solumedrol appear to block IL-12 induced activation of INF-gamma by a mechanism that may be associated with NF-kappa/beta (see Figs. 20-21). This treatment is found to eliminate peritransplant weight gain (Fig. 22) and serum

ATTORNEY DOCKET NO. 14014.0225

hypoproteinemia (Fig. 23), both signs of vascular leak syndrome, which in this study is associated with early graft rejection. This peritransplant treatment regimen can provide a rejection-free window for tolerance
5 induction applicable to cadaveric transplantation.

It takes over 24 hours for IT to exert most of its lymph node T cell killing effects. Therefore, IT cadaveric transplantation protocols (protocols in which
10 organ transplantation occurs generally within 6 hours of initial therapy and not longer than 18 hours) benefit substantially from peritransplant supplemental short term immunosuppressant agents to minimize peritransplant T cell responses to the new organ as shown by the above
15 data.

Throughout this application various publications are referenced by numbers within parentheses. Full citations for these publications are as follows. Also, some
20 publications mentioned hereinabove are hereby incorporated in their entirety by reference. The disclosures of these publications in their entirety are hereby incorporated by reference into this application in order to more fully describe the state of the art to
25 which this invention pertains.

While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a
30 reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention and appended claims.

REFERENCES

1. Nicholls, P. J., Johnson, V. G., Andrew, S. M., Hoogenboom, H. R., Raus, J. C. and Youle, R. J. (1993) *J Biol Chem* 268, 5302-5308.
2. Neville, D. J. (1987) *Ann N Y Acad Sci* 507, 155-1643.
3. Williams, D. P., Parker, K., Bacha, P., Bishai, W., Borowski, M., Genbauffe, F., Strom, T. B. and Murphy, J. R. (1987) *Protein Eng* 1, 493-498
4. Johnson, V. G. and Youle, R. J. (1989) *J Biol Chem* 264, 17739-17744
5. Kreitman, R. J., Chaudhary, V. K., Waldmann, T. A., Hanchard, B., Cranston, B., FitzGerald, D. J. and Pastan, I. (1993) *Leukemia* 7, 553-562
6. Murphy, J. R. (1988) *Cancer Treat Res* 37, 123-124
7. Laske, D. W., Ilercil, O., Akbasak, A., Youle, R. J. and Oldfield, E. H. (1994) *J Neurosurg* 80, 520-526
8. Neville, D. J., Scharff, J. and Srinivasachar, K. (1992) *J of Controlled Release* 24, 133-141
9. Neville, D. J., Scharff, J. and Srinivasachar, K. (1992) *Proc Natl Acad Sci U S A* 89, 2585-2589
10. Giannini, G., Rappuoli, R. and Ratti, G. (1984) *Nucleic Acids Res* 12, 4063-4069
11. Chang, T. M. and Neville, D. M. J. (1977) *J Biol Chem* 252, 1505-1514
12. Neville, D. J., Srinivasachar, K., Stone, R. and Scharff, J. (1989) *J Biol Chem* 264, 14653-14661
13. Shalaby, M. R., Shepard, H. M., Presta, L., Rodrigues, M. L., Beberley, P. C. L., Feldman, M. and Carter, P. (1992) *J Exp Med* 175, 217-225

14. Johnson, S. and Bird, R. E. (1991) in Methods in Enzymol, pp.88-98, Academic Press, Inc., San Diego, California
15. Grimont, F. and Grimont, P. A. D. (1991) in Nucleic acid techniques in bacterial systematics, pp. 252, E. A. G. Stackebrandt M. John Wiley and Sons, LTD, West Sussex, England
16. Esworthy, R. S. and Neville, D. M. J. (1984) J Biol Chem 258, 11496-11504
17. Pelchen-Matthews, A., Armes, J. E., Griffiths, G. and Marsh, M. (1991) J Exp Med 173, 575-578
18. Choe, S., Bennett, M. J., Fujii, G., Curmi, P. M., Kantardjiev, K. A., Collier, R. J. and Eisenberg, D. (1992) Nature 357, 216-222
19. LeMaistre, C. F., Meneghetti, C., Rosenblum, M., Reuben, J., Parker, K., Shaw, J., Deisseroth, A., Woodworth, T. and Parkinson, D. R. (1992) Blood 79, 2547-2554
20. Plataniias, L. C., Ratain, M. J., O'Brien, S., Larson, R. A., Vardiman, J. W., Shaw, J. P., Williams, S. F., Baron, J. M., Parker, K. and Woodworth, T. G. (1994) Leuk Lymphoma 14, 257-262
21. Higashi, K., Asada, H., Kurata, T., Ishikawa, K., Hayami, M., Spriatna, Y., Sutarman, Y. and Yamanishi, K. (1989) J Gen Virol 70, 3171-3176
22. Youle, R. J. and Neville, D. M. J. (1982) J Biol Chem 257, 1598-1601
23. Williams, D. P., Snider, C. E., Strom, T. B. and Murphy, J. R. (1990) J Biol Chem 265, 11885-11889
24. Parlevliet et al. (1992) Transplant Int; 5:234-246.
25. Cosimi et al. (1981) Transplantation;32:535-9.
26. Jaffers et al. (1986) Transplantation;41:572-8.

27. Abramowicz et al. (1989) Transplantation; 47:606-8.
28. Burns et al. (1982) J Immunol;129:1451-7.
29. Parren et al. (1991) Res Immunol; 142:749-63.
30. Waid et al. (1991) Transplant Proc; 23:1062-5.
31. Khazaeli et al. (1994) J Immunotherapy; 15:42-52.
32. Chen C and Okayama H. (1987); Mol Cell Biol
7:2745-52.
33. Slavin-Chiorini et al. (1993) Int J Cancer ;
53:97-103.
34. Rigaut KD, Scharff JE, Neville DM Jr. (1995) Eur J
Immunol;25:2077-82.
35. Woodle ES, Thistlethwaite JR, Jolliffe LK, et al.
(1992) J Immunol;148:2756-63.
36. Miller AD, Rosman GJ. (1989) BioTechniques 7:980-90.
37. Shu LM, Qi CF, Schlom J, Kashmiri SVS (1993) Proc
Natl Acad Sci USA;90:7995-9.
38. Mosmann TR, Williamson AR (1980) Cell; 20:283-92.
39. Capon DJ, Chamow SM, Mordenti J, et al. (1989) Nature
337:525-31.
40. Anand NN, Mandal S, MacKenzie CR, et al. (1991) J Bio
Chem 266:21874-9.
41. Sitia R, Neuberger M, Alberini CM, et al. (1990)
Cell;60:781-90.
42. Alberini CM, Bet P, Milstein C, Sitia R. (1990)
Nature 347:485-7.
43. Fra AM, Fragioli C, Finazzi D, Sitia R, Alberini CM
(1993) The EMBO Journal; 12:4755-61.
44. Wiersma EJ, Shulman MJ (1995); 154:5265-72.
45. Smith KG, Austyn JM, Hariri G, Beverley PC, Morris PJ
(1986) Eur J Immunol; 16:478-86.
46. Tax WJ, Hermes FF, Willems RW, Capel PJ, Koene RA
(1984) J Immunol;133:1185-9.

ATTORNEY DOCKET NO. 14014.0225

47. Lynch, RG, Sandor M., Metzger H, ed. Washington DC: American Society for Microbiology 1990:305-34.
48. Moretta I, Webb SR, Grossi CE, Lydyard M, Cooper MD. (1977) J Exp Med;146:184-200.
49. Ferrarini M, Moretta L, Mingari MC, Tonda P, Pernis B. (1976) Eur J Immunol;6:520-1.
50. Mathur A, Lynch RG, Kohler G (1988);J Immunol; 140:143-7.
51. Pricop L, Rabinowich H, Morel PA, Sulica A, Whiteside TL, Herberman RB (1993) J Immunol; 151:3018-29.
52. Emara M, Sanfilippo F (1992) Cell Immunol; 144:143-54.

ATTORNEY DOCKET NO. 14014.0225

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Neville, David M.
Knechtle, Stuart
- (ii) TITLE OF INVENTION: METHODS OF INDUCING IMMUNE TOLERANCE USING
IMMUNOTOXINS
- (iii) NUMBER OF SEQUENCES: 6
- (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: NEEDLE & ROSENBERG, P.C.
(B) STREET: Suite 1200, 127 Peachtree Street
(C) CITY: Atlanta
(D) STATE: Georgia
(E) COUNTRY: USA
(F) ZIP: 30303
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Spratt, Gwendolyn D.
(B) REGISTRATION NUMBER: 36,016
(C) REFERENCE/DOCKET NUMBER: 14014.0189
- (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 404/688-0770
(B) TELEFAX: 404/688-9880

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 67 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGAAATACC TATTGCCTAC GGCAGCCGCT GGATTGTTAT TACTGCGCTG CCCAACCAGC
GATGGCC

60

67

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 54 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATGAAATACC TATTGCCTAC GGCAGCCGCT GGATTGTTAT TACTCGCTGC CCAA

54

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 59 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGATTGTTAT TACTCGCTGC CCAACAAGCG ATGGCCGGCG CTGATGATGT TGTTGATTC

59

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 31 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CGGTACTATA AAACCTCTTTC CAATCATCGT C

31

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 31 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

ATTORNEY DOCKET NO. 14014.0225

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GACGATGATT GGAAAGAGTT TTATAGTACC G

31

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(E) H can be A or C

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AGATCTGTCG HCTCATCAGC TTTTGATTTC AAAAAATAGC G

40

What is claimed is:

1. A method of inhibiting a rejection response by inducing immune tolerance in a recipient to foreign mammalian donor cells, comprising the steps of:
 - a) exposing the recipient to an immunotoxin so as to safely reduce the recipients's T-cell lymphocyte population by at least 80%; and
 - b) transplanting the donor cells into the recipient, such that a rejection response by the recipient to the donor cell is inhibited.
2. The method of claim 1, wherein the donor cells constitute an organ.
3. The method of claim 1, wherein the donor cells constitute tissue from an organ.
4. The method of claim 1, wherein the donor cells are allogeneic.
5. The method of claim 1, wherein the donor cells are xenogeneic.
6. The method of claim 1, further comprising administering an immunosuppressant compound to enhance the anti-T cell effects of the immunotoxin.
7. The method of claim 6, wherein the immunosuppressant compound is cyclosporin.
8. The method of claim 6, wherein the immunosuppressant compound is mycophenolate mofetil.

ATTORNEY DOCKET NO. 14014.0225

9. The method of claim 6, wherein the immunosuppressant compound is deoxyspergualin.
10. The method of claim 6, wherein the immunosuppressant compound blocks IL-12-induced induction of interferon- γ .
11. The method of claim 1, wherein the exposure step reduces the recipient's T-lymphocyte population by at least 95%.
12. The method of claim 1, further comprising administering a corticosteroid.
13. The method of claim 12, further comprising administering an immunosuppressant compound to enhance the anti-T cell effects of the immunotoxin.
14. The method of claim 13, wherein the immunosuppressant compound is cyclosporin.
15. The method of claim 13, wherein the immunosuppressant compound is mycophenolate mofetil.
16. The method of claim 13, wherein the immunosuppressant compound is deoxyspergualin.
17. The method of claim 13, wherein the immunosuppressant compound blocks IL-12-induced induction of interferon- γ .
18. The method of claim 1, wherein the immunotoxin is administered from several hours before to several days after the transplanting step.

ATTORNEY DOCKET NO. 14014.0225

19. The method of claim 1, wherein the donor cell is from a live donor, and wherein the immunotoxin is administered from 15 hours to 7 days before the transplanting step.

20. The method of claim 1, wherein the donor cell is from a cadaver and is from kidney, and wherein the immunotoxin is administered from 6 to 15 hours before the transplanting step.

21. The method of claim 1, wherein the donor cell is from a cadaver and is selected from the group consisting of heart, lung, liver, pancreas, pancreatic islets and intestine, and wherein the immunotoxin is administered from 0 to 6 hours before the transplanting step.

22. The method of claim 1, wherein the immunosuppressant is administered beginning from about 0 to 6 hours before the transplanting step and continuing for up to several weeks after the transplantation step.

23. The method of claim 1, wherein the immunotoxin comprises an anti-CD3 antibody moiety linked to a diphtheria protein toxin moiety, wherein the toxin moiety has a binding site mutation that reduces binding.

24. The method of claim 23, wherein the immunotoxin is anti-CD3-CRM9.

25. The method of claim 23, further comprising administering a non-toxic mutant of diphtheria toxin before or at the same time as the exposure step.

ABSTRACT

Provided is a method of treating an immune system disorder not involving T cell proliferation, comprising administering to the animal an immunotoxin comprising a mutant diphtheria toxin moiety linked to an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the disorder is treated. Thus, the present method can treat graft-versus-host disease. Also provided is a method of inhibiting a rejection response by inducing immune tolerance in a recipient to a foreign mammalian donor tissue or cells, comprising the steps of: a) exposing the recipient to an immunotoxin so as to reduce the recipients's peripheral blood T-cell lymphocyte population by at least 80%, wherein the immunotoxin is anti-CD3 antibody linked to a diphtheria protein toxin, wherein the protein has a binding site mutation; and b) transplanting the donor cells into the recipient, whereby a rejection response by the recipient to the donor organ cell is inhibited, and the host is tolerized to the donor cell.

Figure 1




Fig. 2 A




Fig. 2 B




Fig. 2C




Fig. 3A




Fig. 3B




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8A




Fig. 8B





Fig. 9

Western Blotting of anti-CD3 Diavalent DT390-scAb



1, 2. non-reduced condition.

2, 4 reduced condition

1, 3 and 2, 4 are two samples

Fig. 10




Fig. 11




Fig. 12

Change orientation of scAb and DT390





Fig. 14



Generating the conjugates of DTMI with UCHT1

Fig. 16

1. Full-length DTMI-scUCHT1



3 483 DTMI-scUCHT1





Fig. 18







Fig. 19B



Serum IL-12 levels after CD3-IT treatment






Fig. 21

Serum IFN- γ levels after CD3-IT treatment




CD3-IT VLS



DAYS POST CD3-IT

000000000000000000

Fig. 23



I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE
60/015,459	4/15/96
60/008,104	10/30/95

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information known by me to be material to the patentability of the claims of this application as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS (MARK APPROPRIATE COLUMN BELOW)		
		PATENTED	PENDING	ABANDONED
08/739,703	10/29/96		X	

I hereby appoint the following attorneys and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

William H. Needle	Reg. No. 26,209	Bradley K. Groff	Reg. No. 39,695
Sumner C. Rosenberg	Reg. No. 28,753	Matthew D. Josephic	Reg. No. 43,699
David G. Perryman	Reg. No. 33,438	David S. Kerven	Reg. No. 43,712
Mitchell A. Katz	Reg. No. 33,919	Janice A. Kimpel	Reg. No. 42,734
Gregory J. Kirsch	Reg. No. 35,572	Tina W. McKeon	Reg. No. 43,791
Gwendolyn D. Spratt	Reg. No. 36,016	Mary L. Miller	Reg. No. 39,303
Nagendra Setty	Reg. No. 38,300	Mark A. Murphy	Reg. No. 42,915
Allan A. Altera	Reg. No. 40,274	Lisa A. Samuels	Reg. No. 43,080
Bryan W. Bockhop	Reg. No. 39,613	Clark G. Sullivan	Reg. No. 36, 942
John L. Capone	Reg. No. 41,656	Elket V. Swope	Reg. No. 40,195
Kean J. DeCarlo	Reg. No. 39,954	Lawrence A. Villanueva	Reg. No. 43,968
LaVonda R. DeWitt	Reg. No. 40,396	Mark A. Westhafer	Reg. No. 42,220
D. Andrew Floam	Reg. No. 34,597		

Address all telephone calls to Gwendolyn D. Spratt at telephone no. (404) 688-0770.

Address all correspondence to:

Gwendolyn D. Spratt, Esq.
NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: David M. Neville

Inventor's signature: _____ Date: _____

Residence: 9624 Parkwood Drive, Bethesda, Maryland 20814, USA

Post Office Address: same

Citizenship: USA

Full name of first inventor: Stuart Knechtle

Inventor's signature:  _____ Date: 6/23/99

Residence: 2268 Caine Road, Oregon, Wisconsin 53575

Post Office Address: same

Citizenship: USA

Full name of first inventor: Judith M. Thomas

Inventor's signature: _____ Date: _____

Residence: 2117 Brook Highland Ridge, Birmingham, Alabama 35242

Post Office Address: same

Citizenship: USA

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE
60/015,459	4/15/96
60/008,104	10/30/95

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information known by me to be material to the patentability of the claims of this application as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS (MARK APPROPRIATE COLUMN BELOW)		
		PATENTED	PENDING	ABANDONED
08/739,703	10/29/96		X	

I hereby appoint the following attorneys and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

William H. Needle	Reg. No. 26,209	Bradley K. Groff	Reg. No. 39,695
Sumner C. Rosenberg	Reg. No. 28,753	Matthew D. Josephic	Reg. No. 43,699
David G. Perryman	Reg. No. 33,438	David S. Kerven	Reg. No. 43,712
Mitchell A. Katz	Reg. No. 33,919	Janice A. Kimpel	Reg. No. 42,734
Gregory J. Kirsch	Reg. No. 35,572	Tina W. McKeon	Reg. No. 43,791
Gwendolyn D. Spratt	Reg. No. 36,016	Mary L. Miller	Reg. No. 39,303
Nagendra Setty	Reg. No. 38,300	Mark A. Murphy	Reg. No. 42,915
Allan A. Altera	Reg. No. 40,274	Lisa A. Samuels	Reg. No. 43,080
Bryan W. Bockhop	Reg. No. 39,613	Clark G. Sullivan	Reg. No. 36, 942
John L. Capone	Reg. No. 41,656	Elket V. Swope	Reg. No. 40,195
Kean J. DeCarlo	Reg. No. 39,954	Lawrence A. Villanueva	Reg. No. 43,968
LaVonda R. DeWitt	Reg. No. 40,396	Mark A. Westhafer	Reg. No. 42,220
D. Andrew Floam	Reg. No. 34,597		

Address all telephone calls to Gwendolyn D. Spratt at telephone no. (404) 688-0770.

Address all correspondence to:

Gwendolyn D. Spratt, Esq.
NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: David M. Neville

Inventor's signature: David M. Neville Date: 7-27-99

Residence: 9624 Parkwood Drive, Bethesda, Maryland 20814, USA

Post Office Address: same

Citizenship: USA

*Stacy C. Willet
Notary Public
My Commission Expires May 1, 2003*

Full name of first inventor: Stuart Knechtle

Inventor's signature: _____ Date: _____

Residence: 2268 Caine Road, Oregon, Wisconsin 53575

Post Office Address: same

Citizenship: USA

Full name of first inventor: Judith M. Thomas

Inventor's signature: _____ Date: _____

Residence: 2117 Brook Highland Ridge, Birmingham, Alabama 35242

Post Office Address: same

Citizenship: USA

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE
60/015,459	4/15/96
60/008,104	10/30/95

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information known by me to be material to the patentability of the claims of this application as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS (MARK APPROPRIATE COLUMN BELOW)		
		PATENTED	PENDING	ABANDONED
08/739,703	10/29/96		X	

I hereby appoint the following attorneys and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

William H. Needle	Reg. No. 26,209	Bradley K. Groff	Reg. No. 39,695
Sumner C. Rosenberg	Reg. No. 28,753	Matthew D. Josephic	Reg. No. 43,699
David G. Perryman	Reg. No. 33,438	David S. Kerven	Reg. No. 43,712
Mitchell A. Katz	Reg. No. 33,919	Janice A. Kimpel	Reg. No. 42,734
Gregory J. Kirsch	Reg. No. 35,572	Tina W. McKeon	Reg. No. 43,791
Gwendolyn D. Spratt	Reg. No. 36,016	Mary L. Miller	Reg. No. 39,303
Nagendra Setty	Reg. No. 38,300	Mark A. Murphy	Reg. No. 42,915
Allan A. Altera	Reg. No. 40,274	Lisa A. Samuels	Reg. No. 43,080
Bryan W. Bockhop	Reg. No. 39,613	Clark G. Sullivan	Reg. No. 36, 942
John L. Capone	Reg. No. 41,656	Elket V. Swope	Reg. No. 40,195
Kean J. DeCarlo	Reg. No. 39,954	Lawrence A. Villanueva	Reg. No. 43,968
LaVonda R. DeWitt	Reg. No. 40,396	Mark A. Westhafer	Reg. No. 42,220
D. Andrew Floam	Reg. No. 34,597		

Address all telephone calls to Gwendolyn D. Spratt at telephone no. (404) 688-0770.

Address all correspondence to:

Gwendolyn D. Spratt, Esq.
NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: David M. Neville

Inventor's signature: _____ Date: _____

Residence: 9624 Parkwood Drive, Bethesda, Maryland 20814, USA

Post Office Address: same

Citizenship: USA

Full name of first inventor: Stuart Knechtle

Inventor's signature: _____ Date: _____

Residence: 2268 Caine Road, Oregon, Wisconsin 53575

Post Office Address: same

Citizenship: USA

Full name of first inventor: Judith M. Thomas


Inventor's signature: Judith M. Thomas Date: 8/10/99

Residence: 2117 Brook Highland Ridge, Birmingham, Alabama 35242

Post Office Address: same

Citizenship: USA

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

25 Sheets of drawings enclosed.

☐ Scanned copy is best available.
